Immunodeficiency 49

Mendelian MONDO:0014981 Pathograph 43 Show in embeddings browser Inborn error of immunity Combined immunodeficiency with syndromic features

Immunodeficiency 49 (IMD49, BCL11B deficiency) is an autosomal dominant inborn error of immunity caused by heterozygous, usually de novo, germline variants in BCL11B, which encodes a C2H2 zinc-finger transcription factor required for commitment of early progenitors to the T-cell lineage and for development of the cortex, hippocampus, craniofacial skeleton, skin and teeth. The index patient was detected by newborn screening for T-cell receptor excision circles (TRECs) and had leaky T-B+NK+ severe combined immunodeficiency together with neonatal teeth, psoriasiform dermatitis, wormian bones, agenesis of the corpus callosum, hypotonia, and later intellectual impairment with spastic quadriplegia and seizures. His heterozygous missense variant (p.N441K) lies in a DNA-contacting zinc finger and acts as a dominant negative: mutant BCL11B heterodimerizes with the wild-type protein, the complex fails to bind canonical target sites and binds at least one novel site, T-lineage development arrests, and hematopoietic progenitor chemokine-receptor expression and migration are disturbed. Hematopoietic stem-cell transplantation fully corrected the immune defect but not the neurodevelopmental disability. Heterozygous truncating variants, whole-gene loss of expression, and most other BCL11B variants cause a related neurodevelopmental disorder (intellectual developmental disorder with speech delay, dysmorphic facies, and T-cell abnormalities, IDDSFTA) with global developmental delay, speech impairment, facial dysmorphism, dental anomalies, refractive errors, craniosynostosis in a subset, movement disorders including dystonia and spasticity, and exaggerated type 2 (atopic) responses. These patients have no overt immunodeficiency but carry a measurable thymopoiesis defect (few recent thymic emigrants and naive CD4+ T cells, an expanded gamma-delta T-cell compartment) and lack peripheral type 2 innate lymphoid cells. The two MONDO/OMIM classes are modelled here as one BCL11B-related disorder spectrum, with IDDSFTA as a subtype.

Ask OpenScientist

Ask a research question about Immunodeficiency 49. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

IUIS Category

👪

Inheritance

Autosomal dominant inheritance HP:0000006

Heterozygous germline BCL11B variants. Almost all reported variants arose de novo; a frameshift allele transmitted from an affected mother to her daughter shows that the disorder can be inherited as an autosomal dominant trait, and a mosaic de novo variant has been reported in one proband.

Autosomal dominant inheritance

Show evidence (2 references)

PMID:27959755 SUPPORT Human Clinical

"The patient’s BCL11B variant was confirmed by Sanger sequencing of DNA from blood and buccal brushings and was found to be a de novo mutation (it was not present in the DNA of either parent)."

De novo heterozygous origin of the variant in the index IMD49 patient.

PMID:29985992 SUPPORT Human Clinical

"A further frameshift mutation was transmitted from a similarly affected mother."

Parent-to-child transmission of a heterozygous allele, consistent with autosomal dominant inheritance.

◆

Subtypes

Intellectual developmental disorder with speech delay, dysmorphic facies, and T-cell abnormalities MONDO:0060763

BCL11B hgnc:13222

The more frequently reported presentation of heterozygous BCL11B variants: global developmental delay, intellectual disability and speech impairment with facial dysmorphism, without overt clinical immunodeficiency but with a measurable T-cell and ILC2 defect. Mostly truncating variants and variants that lower BCL11B expression.

Show evidence (2 references)

PMID:29985992 SUPPORT Human Clinical

"Notably, all of them are affected by global developmental delay with speech impairment and intellectual disability; however, none displayed overt clinical signs of immune deficiency."

Defines the neurodevelopmental presentation in 13 heterozygous patients, distinct from the SCID presentation of the index IMD49 patient.

PMID:40033098 SUPPORT Other

"Our comprehensive review of the literature indicates the absence of a significant distinction between IMD49 and IDDSFTA, either in terms of clinical presentation or molecular mechanism."

Systematic literature review supporting treatment of IDDSFTA and IMD49 as one BCL11B-related disease spectrum, the basis for recording IDDSFTA as a subtype of this entry rather than a separate disease.

⚙

Pathophysiology

Dominant-Negative BCL11B Zinc-Finger Missense Variant

A missense substitution at a DNA-contacting residue of a BCL11B zinc finger (p.N441K in the index IMD49 patient). The mutant protein heterodimerizes with wild-type BCL11B on stimulation, the heterodimer fails to bind canonical target sites, and the mutant also binds a novel site in TACC1, so the allele both removes wild-type function and redirects binding.

BCL11B hgnc:13222

Genetic context allele_type: MISSENSE variant_origin: GERMLINE zygosity: HETEROZYGOUS functional_impact_category: DOMINANT_NEGATIVE

sequence-specific DNA binding GO:0043565 ↓ DECREASED

Downstream

Impaired BCL11B Transcriptional Regulation

Arrest of T-Lineage Commitment and Development

Dysregulated Hematopoietic Progenitor Migration

Show evidence (2 references)

PMID:27959755 SUPPORT In Vitro

"The resulting BCL11B protein had dominant negative activity, which abrogated the ability of wild-type BCL11B to bind DNA, thereby arresting development of the T-cell lineage and disrupting hematopoietic stem-cell migration; this revealed a previously unknown function of BCL11B."

Functional studies in human hematopoietic stem cells and cell lines showing the dominant negative mechanism and its two cellular consequences.

PMID:27959755 SUPPORT In Vitro

"Thus, the p.N441K mutation altered BCL11B function in two ways, by blocking binding to canonical sites while also redirecting binding to novel sites."

ChIP-seq in human hematopoietic stem cells showing loss of canonical binding and gain of novel binding.

BCL11B Haploinsufficiency or Truncation

Frameshift and nonsense variants, balanced translocations that remove BCL11B from its regulatory landscape, and 14q32.2 deletions reduce BCL11B dosage or produce a protein lacking the C-terminal DNA-binding zinc fingers. A C-terminal frameshift allele behaves as a functional null in mouse hippocampal slice cultures.

BCL11B hgnc:13222

Genetic context variant_origin: GERMLINE zygosity: HETEROZYGOUS functional_impact_category: LOSS_OF_FUNCTION

Downstream

Impaired BCL11B Transcriptional Regulation

Show evidence (2 references)

PMID:29985992 SUPPORT Human Clinical

"Taken together, we show here that mutations leading either to BCL11B haploinsufficiency or to a truncated BCL11B protein clinically cause a non-syndromic neurodevelopmental delay."

States the loss-of-function mechanism class and its clinical consequence.

PMID:29985992 SUPPORT Model Organism

"These data suggest that these premature termination codon mutations in BCL11B result in a functional null allele and recapitulate the hippocampal phenotype observed in Bcl11b mutant mice (Simon et al., 2012)."

Mouse hippocampal slice rescue assay showing a patient truncating allele is a functional null.

Reduced BCL11B-NuRD Interaction

An N-terminal missense substitution (p.R3S) in the conserved RRKQxxP motif weakens BCL11B binding to the RBBP4-MTA1 subassembly of the NuRD complex and to PRC2, lowering affinity by nearly an order of magnitude. Reported in isolated coronal craniosynostosis.

BCL11B hgnc:13222

Genetic context allele_type: MISSENSE variant_origin: GERMLINE zygosity: HETEROZYGOUS

Downstream

Abnormal Cranial Suture and Craniofacial Development

Show evidence (1 reference)

PMID:31067316 SUPPORT In Vitro

"The p.R3S substitution occurs within a conserved amino-terminal motif (RRKQxxP) of BCL11B and reduces interaction with both transcriptional complexes."

Biochemical demonstration that the craniosynostosis variant weakens NuRD/PRC2 binding.

Impaired BCL11B Transcriptional Regulation

Shared consequence of the variant classes: reduced BCL11B-dependent regulation of target genes in the tissues where BCL11B specifies cell fate (T-lineage and ILC2 progenitors, cortical and hippocampal neurons, cranial mesenchyme, epidermis and dental epithelium). The critical target genes for morphogenesis and hematopoiesis are not identified.

regulation of DNA-templated transcription GO:0006355 ↓ DECREASED

Downstream

Impaired Thymopoiesis with Skewed T-Cell Compartment

Loss of Type 2 Innate Lymphoid Cells

Abnormal Cortical and Hippocampal Neurodevelopment

Abnormal Cranial Suture and Craniofacial Development

Abnormal Odontogenesis

Abnormal Epidermal Development

Exacerbated Type 2 Helper T-Cell Responses Proposed to follow from loss of BCL11B repression of Th2 differentiation; the intermediate steps in human patients are not established.

Show evidence (2 references)

PMID:27959755 SUPPORT Human Clinical

"BCL11B is a Cys2His2 zinc finger transcription factor, and therefore the observed defects may result from perturbed expression of BCL11B target genes."

The authors' interpretation linking the multisystem phenotype to perturbed BCL11B target-gene expression.

PMID:27959755 SUPPORT Human Clinical

"Nevertheless, the critical target genes required for BCL11B to facilitate morphogenesis and hematopoiesis remain to be identified."

Records that the downstream target genes are unknown.

Arrest of T-Lineage Commitment and Development

BCL11B is induced by Notch signalling and commits progenitors to the T lineage. Knockdown of BCL11B, or expression of the dominant-negative p.N441K allele, abrogates T-cell development from human hematopoietic stem cells without affecting B-cell development, and bcl11ba knockdown blocks T-progenitor development in zebrafish; this is the basis of the T-B+NK+ SCID phenotype.

T cell CL:0000084 double negative thymocyte CL:0002489

T cell differentiation in thymus GO:0033077 ↓ DECREASED

Animal models

bcl11ba morphant zebrafish Zebrafish recapitulates Knockdown or mutant expression blocks T-progenitor development, rescued by wild-type human BCL11B.

Downstream

Severe combined immunodeficiency

Absent T cell receptor excision circles

T lymphopenia

Decreased naive CD4+ T cells

Impaired T-cell proliferation to phytohemagglutinin

Show evidence (3 references)

PMID:27959755 SUPPORT In Vitro

"Moreover, BCL11B played a critical role in the development of human T-cell progenitors, in that their development, but not that of B cells, was impaired by knockdown of BCL11B with the use of siRNA (Fig. 2C and 2D); moreover, ectopic expression of the patient’s mutant construct also abrogated..."

Human hematopoietic stem cells differentiated on OP9-DL1 show a T-lineage-specific block with the patient allele.

PMID:27959755 SUPPORT Model Organism

"Ectopic expression of the p.N441K BCL11B human protein indeed reproduced the abnormalities that were observed on knockdown of bcl11ba; development of T cells marked by lck:GFP was abrogated (Fig. 3A), as was the development of human T-cell progenitors in vitro (Fig. 2D)."

Zebrafish in vivo confirmation that the patient allele blocks T-cell development.

PMID:29985992 SUPPORT BACKGROUND Model Organism

"Indeed, Bcl11b-deficient mice show an arrest at the CD4−CD8− double-negative stage of thymocyte development, resulting in a loss of Tαβ (but not Tγδ cells) and reprogramming to natural killer (NK)-like cells (Wakabayashi et al., 2003; Li et al., 2010)."

Introduction of a human cohort paper summarizing the mouse knockout data that place the T-lineage block at the double-negative thymocyte stage.

Dysregulated Hematopoietic Progenitor Migration

Reduced BCL11B function raises CCR7 and CCR9 expression on hematopoietic progenitors and increases their chemotactic migration; in zebrafish, bcl11ba knockdown displaces progenitors and impairs thymic seeding, which is partially rescued by co-knockdown of ccr9b. This prethymic defect adds to the T-lineage arrest.

hematopoietic stem cell CL:0000037

hematopoietic stem cell migration GO:0035701 ↑ INCREASED

Downstream

Arrest of T-Lineage Commitment and Development

Show evidence (2 references)

PMID:27959755 SUPPORT In Vitro

"In human CD34 progenitors, siRNA-mediated repression of BCL11B also increased the expression of CCR9 as well as CCR7 (Fig. 4D) and increased migration of these progenitors both in response to CCR7 and CCR9 ligands (CCL19 and CCL25, respectively) (Fig. 4E) and in the absence of exogenous chemokines."

Human progenitor transwell assay showing increased chemokine-receptor expression and migration after BCL11B knockdown.

PMID:27959755 SUPPORT Model Organism

"Although the knockdown of ccr9b alone did not prevent thymic seeding, when ccr9b was knocked down in combination with bcl11ba, it did produce a partial rescue of thymic seeding in the bcl11ba morphants at 3.5 and 5 days after fertilization (Fig. 4C, and Fig. S10D in the Supplementary Appendix)."

Zebrafish genetic interaction linking the migration defect to impaired thymic seeding.

Impaired Thymopoiesis with Skewed T-Cell Compartment

In patients without overt immunodeficiency, thymic output is reduced (few CD4+ recent thymic emigrants and naive CD4+ T cells), gamma-delta T cells with a V-delta-1 bias are overrepresented, and effector-memory CD8+ T cells re-expressing CD45RA are expanded, so that patients cluster apart from healthy children on T-cell subset profiling.

T cell CL:0000084 gamma-delta T cell CL:0000798

T cell differentiation in thymus GO:0033077 ↓ DECREASED

Downstream

Decreased recent thymic emigrant CD4+ T cells

Increased gamma-delta T cell proportion

Decreased naive CD4+ T cells

Show evidence (2 references)

PMID:29985992 SUPPORT Human Clinical

"Unsupervised analysis of 102 T lymphocyte subpopulations showed that the patients clearly cluster apart from healthy children, further supporting the common aetiology of the disorder."

Patient T-cell compartments are systematically abnormal despite no overt immunodeficiency.

PMID:37860968 SUPPORT Human Clinical

"We refine the intricacies of T cell compartment alterations of BCL11B-RD, revealing decreased levels naive CD4+ T cells and recent thymic emigrants while concurrently observing an elevated proportion of effector-memory expressing CD45RA CD8+ T cells (TEMRA)."

Independent 20-patient series replicating the reduced thymic output.

Loss of Type 2 Innate Lymphoid Cells

Peripheral ILC2s are severely reduced in number and frequency while total ILCs are normal and ILC3s are not expanded, consistent with a role for BCL11B in ILC2 development as in Bcl11b-deficient mice. This has not been linked to a clinical phenotype; notably it coexists with exaggerated type 2 (atopic) responses.

group 2 innate lymphoid cell CL:0001069

lymphocyte differentiation GO:0030098 ↓ DECREASED

Show evidence (1 reference)

PMID:29985992 SUPPORT Human Clinical

"However, in line with the previously reported findings in mice (Califano et al., 2015; Walker et al., 2015; Yu et al., 2015, 2016) we observed a severe reduction, both in frequency and absolute numbers, of ILC2s in the peripheral innate lymphoid cell compartment (Fig. 5)."

Direct measurement of ILC2 loss in patient blood.

Abnormal Cortical and Hippocampal Neurodevelopment

BCL11B specifies corticospinal motor neurons and striatal medium spiny neurons and drives dentate gyrus progenitor proliferation in mice. Loss or dominant interference in humans produces global developmental delay, intellectual disability and speech impairment, callosal agenesis or dysgenesis in some patients, and motor involvement ranging from hypotonia to spasticity and generalized dystonia.

neuron CL:0000540

dentate gyrus development GO:0021542 ↓ DECREASED corpus callosum development GO:0022038 ⚠ ABNORMAL

Downstream

Intellectual disability

Global developmental delay

Delayed speech and language development

Autistic behavior

Agenesis of corpus callosum

Hypotonia

Spastic tetraplegia

Lower limb spasticity

Seizures

Dystonia

Show evidence (3 references)

PMID:29985992 SUPPORT Model Organism

"This phenotype was completely rescued upon reintroduction of a cDNA construct (pIRES2-EGFP) into the Bcl11b mutant hippocampus containing either wild-type BCL11B (human) or Bcl11b (murine), but not by an equimolar amount of cDNA bearing the mutation as identified in Patient A:II-3 (Fig. 3 and..."

Mouse hippocampal progenitor proliferation depends on BCL11B and is not rescued by a patient allele.

PMID:29985992 SUPPORT Human Clinical

"Notably, all of them are affected by global developmental delay with speech impairment and intellectual disability; however, none displayed overt clinical signs of immune deficiency."

Fully penetrant neurodevelopmental phenotype across a 13-patient cohort.

PMID:28424591 SUPPORT REVIEW SYNTHESIS Other

"Bcl11b is a fundamental transcription factor in fetal development, with important roles for the differentiation and development of various neuronal subtypes in the central nervous system (CNS)."

Review synthesizing the neurodevelopmental roles of Bcl11b that underlie this node.

Abnormal Cranial Suture and Craniofacial Development

BCL11B maintains cranial suture patency and craniofacial cartilage patterning. A knock-in mouse carrying the human p.R3S variant develops coronal and other suture synostoses, and bcl11ba knockdown in zebrafish perturbs head cartilage and widens the interorbital distance.

cranial suture morphogenesis GO:0060363 ⚠ ABNORMAL

Animal models

bcl11ba morphant zebrafish Zebrafish partially recapitulates Head cartilage patterning and interorbital distance are altered.

Bcl11b p.R3S knock-in mouse Mouse recapitulates The knock-in reproduces coronal craniosynostosis seen in the patient.

Downstream

Craniosynostosis

Wormian bones

Facial dysmorphism

Show evidence (2 references)

PMID:31067316 SUPPORT Model Organism

"We generated a mouse model of the BCL11B p.R3S substitution using a CRISPR-Cas9-based approach, and we report herein that these mice exhibit craniosynostosis of the coronal suture, as well as other cranial sutures."

Knock-in mouse recapitulating craniosynostosis from a human BCL11B variant.

PMID:27959755 SUPPORT Model Organism

"Knockdown of bcl11ba in zebrafish also reproduced other developmental abnormalities that were present in the patient, including craniofacial abnormalities and perturbation of the cartilagenous structures in the head (Fig. 2F)."

Zebrafish knockdown reproduces the patient's craniofacial abnormalities.

Abnormal Odontogenesis

Bcl11b is required for tooth development in mice. Patients show natal teeth (index IMD49 patient) and small teeth, oligodontia or enamel defects.

odontogenesis GO:0042476 ⚠ ABNORMAL

Downstream

Natal teeth

Dental anomalies

Show evidence (1 reference)

PMID:29985992 SUPPORT BACKGROUND Model Organism

"Biallelic loss of Bcl11b leads to perinatal lethality in mice, accompanied by defects in the development of the CNS (Arlotta et al., 2005; Simon et al., 2012), the epidermis (Golonzhka et al., 2009a), the teeth (Golonzhka et al., 2009b), as well as in the development and maintenance of the T..."

Introduction of a human cohort paper summarizing mouse knockout data that establishes BCL11B roles in tooth and epidermal development.

Abnormal Epidermal Development

Bcl11b is required for epidermal development in mice. The index IMD49 patient had erythematous psoriasiform dermatitis, and congenital erosive dermatitis occurred in one patient of the first IDDSFTA cohort.

epidermis development GO:0008544 ⚠ ABNORMAL

Downstream

Psoriasiform dermatitis

Show evidence (1 reference)

PMID:29985992 SUPPORT BACKGROUND Model Organism

Background summary of the mouse epidermal phenotype of Bcl11b loss.

Exacerbated Type 2 Helper T-Cell Responses

About half of reported patients have allergic disease (eosinophilia, allergies, asthma, atopic dermatitis). The proposed mechanism is loss of BCL11B's repressive control of Th2 differentiation, which has not been demonstrated in patient cells. It is not explained by ILC2s, which normally drive type 2 inflammation but are reduced in these patients; the Lessel cohort authors suggest that exacerbated Th2 immunity together with the lack of ILC2-mediated epithelial repair may contribute to asthma.

T-helper 2 cell differentiation GO:0045064 ↑ INCREASED

Downstream

Increased eosinophil count

Allergy

Show evidence (4 references)

PMID:29985992 SUPPORT Human Clinical

"In agreement with the previously reported repressive function of BCL11B on Th2 differentiation (Califano et al., 2014), exacerbated Th2 responses were clinically recognized in five patients, including two with asthma (Table 1 and Supplementary Table 2)."

Clinical Th2 exacerbation in five cohort patients, interpreted by the authors in light of BCL11B's known repression of Th2 differentiation (a mouse finding they cite, not one they tested).

PMID:29985992 SUPPORT Human Clinical

"Eight patients showed exacerbated type 2 responses, namely eosinophilia (4/10) and allergies or asthma (7/12) (Fig. 1, Table 1 and Supplementary material)."

Frequency of type 2 manifestations in the cohort.

PMID:34887873 SUPPORT BACKGROUND Human Clinical

"Germline heterozygous variants are associated with a spectrum of clinical disorders, including severe combined immunodeficiency as well as neurological, craniofacial, and dermal defects. Of these individuals, ~50% present with severe allergic disease."

The abstract's framing sentence summarizing previously published BCL11B patients, not this report's own finding.

+ 1 more reference

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Blood 7

Absent T cell receptor excision circles Abnormally low T cell receptor excision circle level HP:0031545

Show evidence (2 references)

PMID:27959755 SUPPORT Human Clinical

"Screening revealed profound T-cell lymphopenia and no detectable TRECs (Table 1)."

Undetectable TRECs on newborn screening.

PMID:29985992 SUPPORT Human Clinical

"Concerning the immune system, the individual bearing a missense mutation (Patient E:II-1) had low T cell receptor excision circles at birth, though T cell measurements at later time points revealed T cell counts close to standard values."

Low TRECs at birth in the zinc-finger missense patient of the IDDSFTA cohort.

T lymphopenia Decreased total T cell count HP:0005403

Show evidence (1 reference)

PMID:27959755 SUPPORT Human Clinical

"Screening revealed profound T-cell lymphopenia and no detectable TRECs (Table 1)."

Profound T-cell lymphopenia in the index patient.

Decreased naive CD4+ T cells Decreased naive CD4+ T cell proportion HP:0410378

Show evidence (2 references)

PMID:27959755 SUPPORT Human Clinical

"Immunologic studies revealed a T-B+NK+ phenotype, with no naive CD4+ helper T cells, an impaired proliferative response to phytohe-magglutinin (Table 1), and no maternal engraftment."

Absent naive CD4+ T cells in the index patient.

PMID:37860968 SUPPORT Human Clinical

Reduced naive CD4+ T cells across a 20-patient series.

Impaired T-cell proliferation to phytohemagglutinin Impaired phytohemagglutinin-induced T lymphocyte transformation HP:0025834

Show evidence (1 reference)

PMID:27959755 SUPPORT Human Clinical

"Immunologic studies revealed a T-B+NK+ phenotype, with no naive CD4+ helper T cells, an impaired proliferative response to phytohe-magglutinin (Table 1), and no maternal engraftment."

Impaired PHA proliferation in the index patient.

Decreased recent thymic emigrant CD4+ T cells Decreased RTE CD4+ T cell proportion HP:0025839

Show evidence (2 references)

PMID:29985992 SUPPORT Human Clinical

"The traits accounting for the differences in the T cell compartment between healthy donors and patients with mutations in BCL11B can be traced to: (i) an abnormally low percentage of CD4+ recent thymic emigrants (Fig. 4B)"

Reduced recent thymic emigrants in IDDSFTA patients.

PMID:37860968 SUPPORT Human Clinical

Replication in an independent series.

Increased gamma-delta T cell proportion HP:0500270

Show evidence (1 reference)

PMID:29985992 SUPPORT Human Clinical

"(ii) an overrepresentation of cells of the Tγδ lineage and TCR Vδ1 bias in detriment of the most common Vδ2γ 9 chains (Fig. 4D)"

Expanded gamma-delta T cells in IDDSFTA patients.

Increased eosinophil count FREQUENT Increased total eosinophil count HP:0001880

Show evidence (1 reference)

PMID:29985992 SUPPORT Human Clinical

"Eight patients showed exacerbated type 2 responses, namely eosinophilia (4/10) and allergies or asthma (7/12) (Fig. 1, Table 1 and Supplementary material)."

Eosinophilia in 4/10 tested patients = 40%, in the FREQUENT band (30-79%).

Cardiovascular 1

Pulmonary artery stenosis HP:0004415

Show evidence (1 reference)

PMID:27959755 SUPPORT Human Clinical

"Imaging (not shown) revealed wormian skull bones, mild pulmonary artery stenosis, and the absence of a corpus callosum."

Pulmonary artery stenosis in the index patient.

Digestive 1

Umbilical hernia HP:0001537

Show evidence (1 reference)

PMID:27959755 SUPPORT Human Clinical

"Abnormal features (Fig. 1A) were accompanied by neonatal teeth, hypotonia, an umbilical hernia, and erythematous psoriaform dermatitis that was responsive to treatment with topical flucinolone."

Umbilical hernia in the index patient.

Eye 1

Abnormality of refraction FREQUENT HP:0000539

Show evidence (1 reference)

PMID:29985992 SUPPORT Human Clinical

"Refractive error was observed in five patients."

5/13 = 38%, in the FREQUENT band (30-79%).

Head and Neck 5

Craniosynostosis HP:0001363

Show evidence (3 references)

PMID:40033098 SUPPORT Human Clinical

"Furthermore, we describe four new patients, all of whom presented with CRS, thus expanding the phenotype of BRD and highlighting CRS as an important diagnostic clue."

Craniosynostosis in four additional patients.

PMID:37337996 SUPPORT Human Clinical

"Notably, craniosynostosis of variable degree was seen in all three individuals."

Craniosynostosis in three further patients with exon 4 frameshift variants.

PMID:31067316 SUPPORT Human Clinical

"Using whole-genome sequencing, we identified a novel, de novo variant in BCL11B, c.7C>A, encoding an R3S substitution (p.R3S), in a male patient with coronal suture synostosis."

Coronal synostosis in a patient with an N-terminal missense variant.

Wormian bones HP:0002645

Show evidence (1 reference)

PMID:27959755 SUPPORT Human Clinical

"Imaging (not shown) revealed wormian skull bones, mild pulmonary artery stenosis, and the absence of a corpus callosum."

Wormian bones in the index IMD49 patient.

Facial dysmorphism Abnormal facial shape HP:0001999

Show evidence (2 references)

PMID:29985992 SUPPORT Human Clinical

"Partially overlapping facial dysmorphisms were observed in all patients."

Facial dysmorphism in all 13 patients.

PMID:37860968 SUPPORT Human Clinical

"Our findings unveil rarely documented clinical manifestations, notably including Rubinstein-Taybi-like facial features, craniosynostosis, and autoimmune disorders, all manifesting within the realm of BCL11B-RD."

Rubinstein-Taybi-like facial features in a further series.

Natal teeth Natal tooth HP:0000695

HPO has no separate neonatal-tooth class; HP:0000695 Natal tooth lists "Neonatal teeth" as a synonym and its definition covers teeth erupting within the first month of life.

Show evidence (1 reference)

PMID:27959755 SUPPORT Human Clinical

"Abnormal features (Fig. 1A) were accompanied by neonatal teeth, hypotonia, an umbilical hernia, and erythematous psoriaform dermatitis that was responsive to treatment with topical flucinolone."

Neonatal teeth in the index patient.

Dental anomalies FREQUENT Abnormality of the dentition HP:0000164

Show evidence (1 reference)

PMID:29985992 SUPPORT Human Clinical

"Small teeth, oligodontia and/or enamel defects were present in five patients."

Dental anomalies in 5/13 patients (38%, FREQUENT band 30-79%), reported jointly.

Immune 4

Severe combined immunodeficiency HP:0004430

Show evidence (2 references)

PMID:27959755 SUPPORT Human Clinical

"The infant had "leaky" SCID (i.e., a form of SCID in which a minimal degree of immune function is preserved), as well as craniofacial and dermal abnormalities and the absence of a corpus callosum; his immune deficit was fully corrected by hematopoietic stem-cell transplantation."

Clinical description of leaky SCID in the index patient.

PMID:27959755 SUPPORT Human Clinical

"Immunologic studies revealed a T-B+NK+ phenotype, with no naive CD4+ helper T cells, an impaired proliferative response to phytohe-magglutinin (Table 1), and no maternal engraftment."

Immunophenotype of the SCID.

Psoriasiform dermatitis HP:0003765

Show evidence (1 reference)

PMID:27959755 SUPPORT Human Clinical

"Abnormal features (Fig. 1A) were accompanied by neonatal teeth, hypotonia, an umbilical hernia, and erythematous psoriaform dermatitis that was responsive to treatment with topical flucinolone."

Psoriasiform dermatitis in the index patient.

Allergy FREQUENT HP:0012393

Show evidence (2 references)

PMID:29985992 SUPPORT Human Clinical

"Eight patients showed exacerbated type 2 responses, namely eosinophilia (4/10) and allergies or asthma (7/12) (Fig. 1, Table 1 and Supplementary material)."

Allergies or asthma in 7/12 patients = 58%, in the FREQUENT band (30-79%).

PMID:34887873 SUPPORT BACKGROUND Human Clinical

About half of previously reported patients have severe allergic disease (framing sentence summarizing earlier reports).

Autoimmunity HP:0002960

Deliberately not connected to a mechanism node. The only source reports autoimmune disorders as a rarely documented manifestation and proposes no mechanism; the reduced thymic output is a plausible but unstated link.

Show evidence (1 reference)

PMID:37860968 SUPPORT Human Clinical

Autoimmune disorders reported in a 20-patient series.

Musculoskeletal 3

Hypotonia HP:0001252

Show evidence (1 reference)

PMID:27959755 SUPPORT Human Clinical

"Abnormal features (Fig. 1A) were accompanied by neonatal teeth, hypotonia, an umbilical hernia, and erythematous psoriaform dermatitis that was responsive to treatment with topical flucinolone."

Neonatal hypotonia in the index patient.

Spastic tetraplegia HP:0002510

Show evidence (1 reference)

PMID:27959755 SUPPORT Human Clinical

"However, he has intellectual impairment, with spastic quadriplegia and seizures."

Spastic quadriplegia in the index IMD49 patient.

Lower limb spasticity HP:0002061

Show evidence (1 reference)

PMID:32659295 SUPPORT Human Clinical

"The second patient had developmental delay, dysmorphic features, spasticity in lower limbs and dental anomalies."

Lower-limb spasticity in a non-SCID patient.

Nervous System 7

Intellectual disability VERY_FREQUENT HP:0001249

Show evidence (2 references)

PMID:29985992 SUPPORT Human Clinical

"Notably, all of them are affected by global developmental delay with speech impairment and intellectual disability; however, none displayed overt clinical signs of immune deficiency."

13/13 in the IDDSFTA cohort. Banded VERY_FREQUENT rather than OBLIGATE because a later 20-patient series describes the disorder as occurring with or without intellectual disability (PMID:37860968).

PMID:27959755 SUPPORT Human Clinical

"However, he has intellectual impairment, with spastic quadriplegia and seizures."

Intellectual impairment in the index IMD49 patient after transplantation.

Global developmental delay VERY_FREQUENT HP:0001263

Show evidence (1 reference)

PMID:29985992 SUPPORT Human Clinical

"Notably, all of them are affected by global developmental delay with speech impairment and intellectual disability; however, none displayed overt clinical signs of immune deficiency."

13/13 in this cohort. Banded VERY_FREQUENT rather than OBLIGATE because an isolated-craniosynostosis patient without systemic findings has been reported (PMID:37337996).

Delayed speech and language development VERY_FREQUENT HP:0000750

Show evidence (1 reference)

PMID:29985992 SUPPORT Human Clinical

"We studied 13 patients affected by global developmental delay and intellectual disability with speech impairment."

13/13 in this cohort. Banded VERY_FREQUENT rather than OBLIGATE because an isolated-craniosynostosis patient without systemic findings has been reported (PMID:37337996).

Autistic behavior FREQUENT HP:0000729

Show evidence (1 reference)

PMID:29985992 SUPPORT Human Clinical

"Autistic features were observed in four patients."

4/13 = 31%, in the FREQUENT band (30-79%).

Agenesis of corpus callosum HP:0001274

Show evidence (2 references)

PMID:27959755 SUPPORT Human Clinical

"Imaging (not shown) revealed wormian skull bones, mild pulmonary artery stenosis, and the absence of a corpus callosum."

Callosal agenesis in the index IMD49 patient.

PMID:32659295 SUPPORT Human Clinical

"She also had dysgenesis of corpus callosum and dilatation of the frontal horns of lateral ventricles, a brain anomaly that has been previously reported in only one other patient."

Callosal dysgenesis in a second, non-SCID patient.

Seizures HP:0001250

Show evidence (1 reference)

PMID:27959755 SUPPORT Human Clinical

"However, he has intellectual impairment, with spastic quadriplegia and seizures."

Seizures in the index IMD49 patient.

Dystonia HP:0001332

Show evidence (2 references)

PMID:38801144 SUPPORT Human Clinical

"Recent case reports suggested that a complex movement disorder (MD) including spasticity and dystonia can be part of the phenotypic spectrum."

Movement disorders reported across several BCL11B case reports.

PMID:38801144 SUPPORT Human Clinical

"Here, we report on a young girl with childhood‐onset generalized dystonia and ID carrying a de novo, likely pathogenic BCL11B variant."

Case report of progressive generalized dystonia.

🧬

Genetic Associations

BCL11B (CAUSATIVE)

Gene: BCL11B hgnc:13222 variant_origin: GERMLINE

Show evidence (3 references)

PMID:27959755 SUPPORT Human Clinical

"Exome sequencing revealed a heterozygous de novo missense mutation, p.N441K, in BCL11B."

Identification of the causal BCL11B variant in the index IMD49 patient.

PMID:29985992 SUPPORT Human Clinical

"Using massively parallel sequencing we identified 13 patients bearing heterozygous germline alterations in BCL11B."

Independent cohort establishing heterozygous BCL11B variants as a cause of the neurodevelopmental presentation.

PMID:29985992 SUPPORT Human Clinical

"Interestingly, the most severely affected patient harbours a missense mutation within a zinc-finger domain of BCL11B, probably affecting the DNA-binding structural interface, similar to the recently published patient."

Supports the genotype-severity relationship between zinc-finger missense variants and severe disease.

💊

Medical Actions

Hematopoietic Stem Cell Transplantation

Action: allogeneic hematopoietic stem cell transplantation Ontology label: Hematopoietic Cell Transplantation NCIT:C15431

Platform: Cell therapy

Allogeneic HSCT (a second transplant after conditioning with busulfan, fludarabine and antithymocyte globulin, following failed engraftment of the first) gave full T-cell engraftment, normal PHA proliferation, a normal T-cell-receptor repertoire and protective vaccine responses in the index IMD49 patient. It does not correct the neurodevelopmental disability.

Mechanism Target:

Arrest of T-Lineage Commitment and Development — Donor-derived hematopoiesis supplies BCL11B-sufficient T-lineage progenitors.

Show evidence (2 references)

PMID:27959755 SUPPORT Human Clinical

"By 2 years of age, the patient no longer required any medication and had protective vaccine responses; engraftment has remained stable."

Durable immune reconstitution after HSCT.

PMID:27959755 SUPPORT Human Clinical

"This was critical for our patient, who, despite having substantial developmental abnormalities outside the hematopoietic system, had full hematopoietic reconstitution after stem-cell transplantation."

Immune correction despite persistent non-hematopoietic abnormalities.

Antimicrobial Prophylaxis and Immunoglobulin Replacement

Action: anti-infective prophylaxis and intravenous immune globulin Ontology label: Supportive Care NCIT:C15747

Pre-transplant supportive care for the SCID presentation: anti-infective prophylaxis and intravenous immune globulin.

Mechanism Target:

Severe combined immunodeficiency — Prevents infection while T-cell immunity is absent.

Show evidence (1 reference)

PMID:27959755 SUPPORT Human Clinical

"The infant received antiinfective prophylaxis and intravenous immune globulin."

Supportive care given before transplantation.

🔬

Diagnosis

TREC-Based Newborn Screening

The SCID presentation is detectable at birth by quantification of T-cell receptor excision circles on the newborn dried blood spot; the index IMD49 patient had no detectable TRECs and was identified and transplanted before any infection. Low TRECs at birth were also recorded in a zinc-finger missense patient of the IDDSFTA cohort whose later T-cell counts were near normal, so a low TREC result does not by itself separate the two presentations.

TREC newborn screening NCIT:C81178

Show evidence (2 references)

PMID:27959755 SUPPORT Human Clinical

"Newborn screening facilitated the identification and treatment of a previously unknown cause of human SCID."

TREC newborn screening identified the index IMD49 patient.

PMID:27959755 SUPPORT Human Clinical

"SCID was detected in a newborn before the onset of infections by means of screening of T-cell-receptor excision circles, a biomarker for thymic output."

Detection by TREC screening before infections.

BCL11B Sequencing and Copy-Number Analysis

Diagnosis is molecular: heterozygous BCL11B variants have been found by trio exome sequencing and genome sequencing. Deletions of 14q32.2 that include BCL11B also cause the disorder, so targeted copy-number analysis is advised when sequencing is negative and the disorder is suspected.

exome or genome sequencing NCIT:C101295

Show evidence (3 references)

PMID:27959755 SUPPORT Human Clinical

"Exome sequencing revealed a heterozygous de novo missense mutation, p.N441K, in BCL11B."

Trio exome sequencing established the diagnosis in the index patient.

PMID:29985992 SUPPORT Human Clinical

"Using massively parallel sequencing we identified 13 patients bearing heterozygous germline alterations in BCL11B."

Massively parallel sequencing identified the IDDSFTA cohort.

PMID:40033098 SUPPORT Human Clinical

"Finally, we show that BCL11B has been underappreciated as a contributor to the phenotype resulting from 14q32 microdeletion and that where BRD is suspected, targeted copy number analysis should be undertaken after negative sequencing results."

Recommends copy-number analysis after negative sequencing.

BCL11B DNA Methylation Episignature

Peripheral blood DNA methylation profiling identifies a BCL11B-specific episignature that distinguishes affected individuals from controls and from other neurodevelopmental disorders with established episignatures, and can be used to reclassify BCL11B variants of uncertain significance.

genome-wide DNA methylation episignature analysis NCIT:C63328

Show evidence (2 references)

PMID:37860968 SUPPORT Human Clinical

"Finally, a distinct DNA methylation episignature exclusive to BCL11B-RD is unveiled."

Identification of the episignature.

PMID:37860968 SUPPORT Human Clinical

"Moreover, the identification of a unique DNA methylation episignature offers a valuable diagnosis tool for BCL11B-RD, thereby facilitating routine clinical practice by empowering physicians to reevaluate variants of uncertain significance within the BCL11B gene."

States the diagnostic use of the episignature for variant reclassification.

🐁

Animal Models

bcl11ba morphant zebrafish

Morpholino knockdown of the zebrafish BCL11B orthologue bcl11ba, and ectopic expression of the patient's p.N441K allele, block lck:GFP T-progenitor development, perturb head cartilage, widen interorbital distance and displace hematopoietic progenitors; wild-type but not mutant human BCL11B rescues.

Species

Zebrafish

Genotype

bcl11ba antisense morpholino knockdown, with or without ectopic human BCL11B p.N441K

Publication

PMID:27959755

Pathograph links

Arrest of T-Lineage Commitment and Development recapitulates fidelity: moderate Knockdown or mutant expression blocks T-progenitor development, rescued by wild-type human BCL11B.

Limitations: Transient morpholino knockdown in embryos rather than a stable heterozygous allele; embryonic thymus seeding rather than postnatal human thymopoiesis.

Show evidence (1 reference)

PMID:27959755 SUPPORT Model Organism

"Indeed, although re-expression of wild-type human BCL11B protein restored T-cell development and corrected the craniofacial abnormalities associated with its loss, human p.N441K BCL11B failed to do so (Fig. 3D)."

Rescue experiment establishing the model's specificity for the T-lineage defect.

Abnormal Cranial Suture and Craniofacial Development partially recapitulates fidelity: low Head cartilage patterning and interorbital distance are altered.

Limitations: Zebrafish embryonic cartilage patterning is not cranial suture biology; the model does not address craniosynostosis.

Show evidence (1 reference)

PMID:27959755 SUPPORT Model Organism

Craniofacial phenotype in the morphants.

Bcl11b p.R3S knock-in mouse

Mouse carrying the human craniosynostosis BCL11B p.R3S substitution, which weakens binding to NuRD and PRC2; it develops coronal and other suture synostoses.

Species

Mouse

Genotype

Bcl11b p.R3S (CRISPR-Cas9 knock-in)

Publication

PMID:31067316

Pathograph links

Abnormal Cranial Suture and Craniofacial Development recapitulates fidelity: high The knock-in reproduces coronal craniosynostosis seen in the patient.

Show evidence (1 reference)

PMID:31067316 SUPPORT Model Organism

Knock-in mouse craniosynostosis.

{ }

Source YAML

click to show

name: Immunodeficiency 49
creation_date: "2026-09-28T12:46:47Z"
category: Mendelian
synonyms:
- IMD49
- BCL11B deficiency
- Severe combined immunodeficiency, T cell-negative, B cell-positive, NK cell-positive, with intellectual disability, spasticity, and craniofacial abnormalities
- BCL11B primary immunodeficiency disease
description: >
  Immunodeficiency 49 (IMD49, BCL11B deficiency) is an autosomal dominant inborn
  error of immunity caused by heterozygous, usually de novo, germline variants in
  BCL11B, which encodes a C2H2 zinc-finger transcription factor required for
  commitment of early progenitors to the T-cell lineage and for development of the
  cortex, hippocampus, craniofacial skeleton, skin and teeth. The index patient was
  detected by newborn screening for T-cell receptor excision circles (TRECs) and had
  leaky T-B+NK+ severe combined immunodeficiency together with neonatal teeth,
  psoriasiform dermatitis, wormian bones, agenesis of the corpus callosum,
  hypotonia, and later intellectual impairment with spastic quadriplegia and
  seizures. His heterozygous missense variant (p.N441K) lies in a DNA-contacting
  zinc finger and acts as a dominant negative: mutant BCL11B heterodimerizes with
  the wild-type protein, the complex fails to bind canonical target sites and binds
  at least one novel site, T-lineage development arrests, and hematopoietic
  progenitor chemokine-receptor expression and migration are disturbed.
  Hematopoietic stem-cell transplantation fully corrected the immune defect but not
  the neurodevelopmental disability.

  Heterozygous truncating variants, whole-gene loss of expression, and most other
  BCL11B variants cause a related neurodevelopmental disorder (intellectual
  developmental disorder with speech delay, dysmorphic facies, and T-cell
  abnormalities, IDDSFTA) with global developmental delay, speech impairment,
  facial dysmorphism, dental anomalies, refractive errors, craniosynostosis in a
  subset, movement disorders including dystonia and spasticity, and exaggerated
  type 2 (atopic) responses. These patients have no overt immunodeficiency but carry
  a measurable thymopoiesis defect (few recent thymic emigrants and naive CD4+ T
  cells, an expanded gamma-delta T-cell compartment) and lack peripheral type 2
  innate lymphoid cells. The two MONDO/OMIM classes are modelled here as one
  BCL11B-related disorder spectrum, with IDDSFTA as a subtype.
disease_term:
  preferred_term: immunodeficiency 49
  term:
    id: MONDO:0014981
    label: immunodeficiency 49
parents:
- Inborn error of immunity
- Combined immunodeficiency with syndromic features
notes: >-
  Lump/split: MONDO keeps immunodeficiency 49 (MONDO:0014981, OMIM:617237) and
  intellectual developmental disorder with speech delay, dysmorphic facies, and
  t-cell abnormalities (MONDO:0060763, OMIM:618092) as separate classes. The second
  is recorded here as a has_subtypes row rather than a separate entry because both
  are heterozygous BCL11B disorders sharing the same T-cell, ILC2, neurodevelopmental
  and craniofacial mechanisms; a systematic review (PMID:40033098) found no
  significant clinical or molecular distinction between them, and the IDDSFTA cohort
  that defined OMIM:618092 (PMID:29985992) already carries the subclinical T-cell
  defect. The proposed genotype split (a zinc-finger DNA-contact missense acting as
  a dominant negative gives the severe SCID presentation; truncation or reduced
  expression gives the neurodevelopmental presentation) is recorded as two root
  pathophysiology nodes. IUIS 2022 lists BCL11B deficiency with the combined
  immunodeficiencies with associated or syndromic features, which is why the SCID
  genetics entry (Severe_Combined_Immunodeficiency) does not carry BCL11B.
references:
- reference: PMID:27959755
  title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
- reference: PMID:29985992
  title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
- reference: PMID:37860968
  title: "Clinico-biological refinement of BCL11B-related disorder and identification of an episignature: A series of 20 unreported individuals."
- reference: PMID:40033098
  title: "BCL11B-related disease: a single phenotypic entity?"
- reference: PMID:28424591
  title: "Bcl11b-A Critical Neurodevelopmental Transcription Factor-Roles in Health and Disease."
- reference: PMID:35748970
  title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
classifications:
  iuis_category:
    classification_value: combined immunodeficiency with syndromic features
    notes: >-
      IUIS 2022 Table 2 (combined immunodeficiencies with associated or syndromic
      features), BCL11B deficiency row, listed between SP110 (VODI) and EPG5 (Vici
      syndrome). The cached source is PDF-extracted text, so the snippet reproduces
      the extraction's broken word spacing at the column boundaries.
    evidence:
    - reference: PMID:35748970
      reference_title: "Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "BCL11B deficiency BCL11B AD 617237 Low, poor proliferationN ormalN ormalC ongenital abnormalities, neonatal teeth, dysmorphic facies; absent corpus callosum, neurocognitive deficits"
      explanation: >-
        The complete IUIS row for BCL11B deficiency: autosomal dominant, OMIM
        617237, low T cells with poor proliferation, normal B and NK cells, and
        the syndromic features. Its placement in the syndromic combined
        immunodeficiency table is the classification assertion.
has_subtypes:
- name: IDDSFTA
  display_name: Intellectual developmental disorder with speech delay, dysmorphic facies, and T-cell abnormalities
  classification: clinical_phenotype
  subtype_term:
    preferred_term: intellectual developmental disorder with speech delay, dysmorphic facies, and T-cell abnormalities
    term:
      id: MONDO:0060763
      label: intellectual developmental disorder with speech delay, dysmorphic facies, and t-cell abnormalities
  description: >-
    The more frequently reported presentation of heterozygous BCL11B variants:
    global developmental delay, intellectual disability and speech impairment with
    facial dysmorphism, without overt clinical immunodeficiency but with a
    measurable T-cell and ILC2 defect. Mostly truncating variants and variants that
    lower BCL11B expression.
  genes:
  - preferred_term: BCL11B
    term:
      id: hgnc:13222
      label: BCL11B
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Notably, all of them are affected by global developmental delay with speech impairment and intellectual disability; however, none displayed overt clinical signs of immune deficiency."
    explanation: >-
      Defines the neurodevelopmental presentation in 13 heterozygous patients,
      distinct from the SCID presentation of the index IMD49 patient.
  - reference: PMID:40033098
    reference_title: "BCL11B-related disease: a single phenotypic entity?"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Our comprehensive review of the literature indicates the absence of a significant distinction between IMD49 and IDDSFTA, either in terms of clinical presentation or molecular mechanism."
    explanation: >-
      Systematic literature review supporting treatment of IDDSFTA and IMD49 as one
      BCL11B-related disease spectrum, the basis for recording IDDSFTA as a subtype
      of this entry rather than a separate disease.
inheritance:
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >
    Heterozygous germline BCL11B variants. Almost all reported variants arose de novo;
    a frameshift allele transmitted from an affected mother to her daughter shows
    that the disorder can be inherited as an autosomal dominant trait, and a mosaic
    de novo variant has been reported in one proband.
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient’s BCL11B variant was confirmed by Sanger sequencing of DNA from blood and buccal brushings and was found to be a de novo mutation (it was not present in the DNA of either parent)."
    explanation: De novo heterozygous origin of the variant in the index IMD49 patient.
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A further frameshift mutation was transmitted from a similarly affected mother."
    explanation: Parent-to-child transmission of a heterozygous allele, consistent with autosomal dominant inheritance.
genetic:
- name: BCL11B
  gene_term:
    preferred_term: BCL11B
    term:
      id: hgnc:13222
      label: BCL11B
  association: CAUSATIVE
  variant_origin: GERMLINE
  features: >
    Heterozygous germline variants. The SCID presentation is associated with a
    missense variant (p.N441K) at a DNA-contacting residue of zinc finger 2 that
    acts as a dominant negative; a second zinc-finger DNA-recognition missense
    (p.N807K, zinc finger 4) gave the most severe phenotype of the first IDDSFTA
    cohort. Frameshift and nonsense variants (most in the last exon, predicted to
    escape nonsense-mediated decay and to delete the C-terminal zinc fingers),
    balanced translocations that separate BCL11B from its enhancers and halve its
    expression, and 14q32.2 deletions give the neurodevelopmental presentation. An
    N-terminal missense (p.R3S) that weakens binding to the NuRD and PRC2
    complexes was found in isolated coronal craniosynostosis.
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Exome sequencing revealed a heterozygous de novo missense mutation, p.N441K, in BCL11B."
    explanation: Identification of the causal BCL11B variant in the index IMD49 patient.
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using massively parallel sequencing we identified 13 patients bearing heterozygous germline alterations in BCL11B."
    explanation: Independent cohort establishing heterozygous BCL11B variants as a cause of the neurodevelopmental presentation.
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Interestingly, the most severely affected patient harbours a missense mutation within a zinc-finger domain of BCL11B, probably affecting the DNA-binding structural interface, similar to the recently published patient."
    explanation: Supports the genotype-severity relationship between zinc-finger missense variants and severe disease.
pathophysiology:
- name: Dominant-Negative BCL11B Zinc-Finger Missense Variant
  biological_scale: MOLECULAR
  genetic_context:
    allele_type: MISSENSE
    variant_origin: GERMLINE
    zygosity: HETEROZYGOUS
    functional_impact_category: DOMINANT_NEGATIVE
  description: >
    A missense substitution at a DNA-contacting residue of a BCL11B zinc finger
    (p.N441K in the index IMD49 patient). The mutant protein heterodimerizes with
    wild-type BCL11B on stimulation, the heterodimer fails to bind canonical target
    sites, and the mutant also binds a novel site in TACC1, so the allele both
    removes wild-type function and redirects binding.
  genes:
  - preferred_term: BCL11B
    term:
      id: hgnc:13222
      label: BCL11B
  molecular_functions:
  - preferred_term: sequence-specific DNA binding
    term:
      id: GO:0043565
      label: sequence-specific DNA binding
    modifier: DECREASED
  downstream:
  - target: Impaired BCL11B Transcriptional Regulation
  - target: Arrest of T-Lineage Commitment and Development
  - target: Dysregulated Hematopoietic Progenitor Migration
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The resulting BCL11B protein had dominant negative activity, which abrogated the ability of wild-type BCL11B to bind DNA, thereby arresting development of the T-cell lineage and disrupting hematopoietic stem-cell migration; this revealed a previously unknown function of BCL11B."
    explanation: >-
      Functional studies in human hematopoietic stem cells and cell lines showing the
      dominant negative mechanism and its two cellular consequences.
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Thus, the p.N441K mutation altered BCL11B function in two ways, by blocking binding to canonical sites while also redirecting binding to novel sites."
    explanation: ChIP-seq in human hematopoietic stem cells showing loss of canonical binding and gain of novel binding.
- name: BCL11B Haploinsufficiency or Truncation
  biological_scale: MOLECULAR
  genetic_context:
    variant_origin: GERMLINE
    zygosity: HETEROZYGOUS
    functional_impact_category: LOSS_OF_FUNCTION
  description: >
    Frameshift and nonsense variants, balanced translocations that remove BCL11B
    from its regulatory landscape, and 14q32.2 deletions reduce BCL11B dosage or
    produce a protein lacking the C-terminal DNA-binding zinc fingers. A C-terminal
    frameshift allele behaves as a functional null in mouse hippocampal slice
    cultures.
  genes:
  - preferred_term: BCL11B
    term:
      id: hgnc:13222
      label: BCL11B
  downstream:
  - target: Impaired BCL11B Transcriptional Regulation
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Taken together, we show here that mutations leading either to BCL11B haploinsufficiency or to a truncated BCL11B protein clinically cause a non-syndromic neurodevelopmental delay."
    explanation: States the loss-of-function mechanism class and its clinical consequence.
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These data suggest that these premature termination codon mutations in BCL11B result in a functional null allele and recapitulate the hippocampal phenotype observed in Bcl11b mutant mice (Simon et al., 2012)."
    explanation: Mouse hippocampal slice rescue assay showing a patient truncating allele is a functional null.
- name: Reduced BCL11B-NuRD Interaction
  biological_scale: MOLECULAR
  genetic_context:
    allele_type: MISSENSE
    variant_origin: GERMLINE
    zygosity: HETEROZYGOUS
  description: >
    An N-terminal missense substitution (p.R3S) in the conserved RRKQxxP motif
    weakens BCL11B binding to the RBBP4-MTA1 subassembly of the NuRD complex and to
    PRC2, lowering affinity by nearly an order of magnitude. Reported in isolated
    coronal craniosynostosis.
  genes:
  - preferred_term: BCL11B
    term:
      id: hgnc:13222
      label: BCL11B
  downstream:
  - target: Abnormal Cranial Suture and Craniofacial Development
  evidence:
  - reference: PMID:31067316
    reference_title: "A de novo substitution in BCL11B leads to loss of interaction with transcriptional complexes and craniosynostosis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The p.R3S substitution occurs within a conserved amino-terminal motif (RRKQxxP) of BCL11B and reduces interaction with both transcriptional complexes."
    explanation: Biochemical demonstration that the craniosynostosis variant weakens NuRD/PRC2 binding.
- name: Impaired BCL11B Transcriptional Regulation
  biological_scale: MOLECULAR
  description: >
    Shared consequence of the variant classes: reduced BCL11B-dependent regulation
    of target genes in the tissues where BCL11B specifies cell fate (T-lineage and
    ILC2 progenitors, cortical and hippocampal neurons, cranial mesenchyme,
    epidermis and dental epithelium). The critical target genes for morphogenesis
    and hematopoiesis are not identified.
  biological_processes:
  - preferred_term: regulation of DNA-templated transcription
    term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
    modifier: DECREASED
  downstream:
  - target: Impaired Thymopoiesis with Skewed T-Cell Compartment
  - target: Loss of Type 2 Innate Lymphoid Cells
  - target: Abnormal Cortical and Hippocampal Neurodevelopment
  - target: Abnormal Cranial Suture and Craniofacial Development
  - target: Abnormal Odontogenesis
  - target: Abnormal Epidermal Development
  - target: Exacerbated Type 2 Helper T-Cell Responses
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Proposed to follow from loss of BCL11B repression of Th2 differentiation;
      the intermediate steps in human patients are not established.
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BCL11B is a Cys2His2 zinc finger transcription factor, and therefore the observed defects may result from perturbed expression of BCL11B target genes."
    explanation: >-
      The authors' interpretation linking the multisystem phenotype to perturbed
      BCL11B target-gene expression.
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nevertheless, the critical target genes required for BCL11B to facilitate morphogenesis and hematopoiesis remain to be identified."
    explanation: Records that the downstream target genes are unknown.
- name: Arrest of T-Lineage Commitment and Development
  biological_scale: CELLULAR
  description: >
    BCL11B is induced by Notch signalling and commits progenitors to the T lineage.
    Knockdown of BCL11B, or expression of the dominant-negative p.N441K allele,
    abrogates T-cell development from human hematopoietic stem cells without
    affecting B-cell development, and bcl11ba knockdown blocks T-progenitor
    development in zebrafish; this is the basis of the T-B+NK+ SCID phenotype.
  cell_types:
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: double negative thymocyte
    term:
      id: CL:0002489
      label: double negative thymocyte
  biological_processes:
  - preferred_term: T cell differentiation in thymus
    term:
      id: GO:0033077
      label: T cell differentiation in thymus
    modifier: DECREASED
  downstream:
  - target: Severe combined immunodeficiency
  - target: Absent T cell receptor excision circles
  - target: T lymphopenia
  - target: Decreased naive CD4+ T cells
  - target: Impaired T-cell proliferation to phytohemagglutinin
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Moreover, BCL11B played a critical role in the development of human T-cell progenitors, in that their development, but not that of B cells, was impaired by knockdown of BCL11B with the use of siRNA (Fig. 2C and 2D); moreover, ectopic expression of the patient’s mutant construct also abrogated T-cell development, which suggested a dominant negative effect."
    explanation: Human hematopoietic stem cells differentiated on OP9-DL1 show a T-lineage-specific block with the patient allele.
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Ectopic expression of the p.N441K BCL11B human protein indeed reproduced the abnormalities that were observed on knockdown of bcl11ba; development of T cells marked by lck:GFP was abrogated (Fig. 3A), as was the development of human T-cell progenitors in vitro (Fig. 2D)."
    explanation: Zebrafish in vivo confirmation that the patient allele blocks T-cell development.
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: BACKGROUND
    snippet: "Indeed, Bcl11b-deficient mice show an arrest at the CD4−CD8− double-negative stage of thymocyte development, resulting in a loss of Tαβ (but not Tγδ cells) and reprogramming to natural killer (NK)-like cells (Wakabayashi et al., 2003; Li et al., 2010)."
    explanation: >-
      Introduction of a human cohort paper summarizing the mouse knockout data that
      place the T-lineage block at the double-negative thymocyte stage.
- name: Dysregulated Hematopoietic Progenitor Migration
  biological_scale: CELLULAR
  description: >
    Reduced BCL11B function raises CCR7 and CCR9 expression on hematopoietic
    progenitors and increases their chemotactic migration; in zebrafish, bcl11ba
    knockdown displaces progenitors and impairs thymic seeding, which is partially
    rescued by co-knockdown of ccr9b. This prethymic defect adds to the T-lineage
    arrest.
  cell_types:
  - preferred_term: hematopoietic stem cell
    term:
      id: CL:0000037
      label: hematopoietic stem cell
  biological_processes:
  - preferred_term: hematopoietic stem cell migration
    term:
      id: GO:0035701
      label: hematopoietic stem cell migration
    modifier: INCREASED
  downstream:
  - target: Arrest of T-Lineage Commitment and Development
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In human CD34 progenitors, siRNA-mediated repression of BCL11B also increased the expression of CCR9 as well as CCR7 (Fig. 4D) and increased migration of these progenitors both in response to CCR7 and CCR9 ligands (CCL19 and CCL25, respectively) (Fig. 4E) and in the absence of exogenous chemokines."
    explanation: Human progenitor transwell assay showing increased chemokine-receptor expression and migration after BCL11B knockdown.
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Although the knockdown of ccr9b alone did not prevent thymic seeding, when ccr9b was knocked down in combination with bcl11ba, it did produce a partial rescue of thymic seeding in the bcl11ba morphants at 3.5 and 5 days after fertilization (Fig. 4C, and Fig. S10D in the Supplementary Appendix)."
    explanation: Zebrafish genetic interaction linking the migration defect to impaired thymic seeding.
- name: Impaired Thymopoiesis with Skewed T-Cell Compartment
  biological_scale: CELLULAR
  description: >
    In patients without overt immunodeficiency, thymic output is reduced (few CD4+
    recent thymic emigrants and naive CD4+ T cells), gamma-delta T cells with a
    V-delta-1 bias are overrepresented, and effector-memory CD8+ T cells
    re-expressing CD45RA are expanded, so that patients cluster apart from healthy
    children on T-cell subset profiling.
  cell_types:
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: gamma-delta T cell
    term:
      id: CL:0000798
      label: gamma-delta T cell
  biological_processes:
  - preferred_term: T cell differentiation in thymus
    term:
      id: GO:0033077
      label: T cell differentiation in thymus
    modifier: DECREASED
  downstream:
  - target: Decreased recent thymic emigrant CD4+ T cells
  - target: Increased gamma-delta T cell proportion
  - target: Decreased naive CD4+ T cells
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unsupervised analysis of 102 T lymphocyte subpopulations showed that the patients clearly cluster apart from healthy children, further supporting the common aetiology of the disorder."
    explanation: Patient T-cell compartments are systematically abnormal despite no overt immunodeficiency.
  - reference: PMID:37860968
    reference_title: "Clinico-biological refinement of BCL11B-related disorder and identification of an episignature: A series of 20 unreported individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We refine the intricacies of T cell compartment alterations of BCL11B-RD, revealing decreased levels naive CD4+ T cells and recent thymic emigrants while concurrently observing an elevated proportion of effector-memory expressing CD45RA CD8+ T cells (TEMRA)."
    explanation: Independent 20-patient series replicating the reduced thymic output.
- name: Loss of Type 2 Innate Lymphoid Cells
  biological_scale: CELLULAR
  description: >
    Peripheral ILC2s are severely reduced in number and frequency while total ILCs
    are normal and ILC3s are not expanded, consistent with a role for BCL11B in ILC2
    development as in Bcl11b-deficient mice. This has not been linked to a clinical
    phenotype; notably it coexists with exaggerated type 2 (atopic) responses.
  cell_types:
  - preferred_term: group 2 innate lymphoid cell
    term:
      id: CL:0001069
      label: group 2 innate lymphoid cell
  biological_processes:
  - preferred_term: lymphocyte differentiation
    term:
      id: GO:0030098
      label: lymphocyte differentiation
    modifier: DECREASED
  notes: >-
    GO has no innate lymphoid cell or ILC2 differentiation term: the children of
    GO:0030098 lymphocyte differentiation are B cell, T cell and natural killer
    cell differentiation, and an OLS search of GO for "innate lymphoid cell
    differentiation" returns no GO class. The ILC2 specificity is carried by the
    cell_types binding.
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, in line with the previously reported findings in mice (Califano et al., 2015; Walker et al., 2015; Yu et al., 2015, 2016) we observed a severe reduction, both in frequency and absolute numbers, of ILC2s in the peripheral innate lymphoid cell compartment (Fig. 5)."
    explanation: Direct measurement of ILC2 loss in patient blood.
- name: Abnormal Cortical and Hippocampal Neurodevelopment
  biological_scale: TISSUE
  description: >
    BCL11B specifies corticospinal motor neurons and striatal medium spiny neurons
    and drives dentate gyrus progenitor proliferation in mice. Loss or dominant
    interference in humans produces global developmental delay, intellectual
    disability and speech impairment, callosal agenesis or dysgenesis in some
    patients, and motor involvement ranging from hypotonia to spasticity and
    generalized dystonia.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: dentate gyrus development
    term:
      id: GO:0021542
      label: dentate gyrus development
    modifier: DECREASED
  - preferred_term: corpus callosum development
    term:
      id: GO:0022038
      label: corpus callosum development
    modifier: ABNORMAL
  downstream:
  - target: Intellectual disability
  - target: Global developmental delay
  - target: Delayed speech and language development
  - target: Autistic behavior
  - target: Agenesis of corpus callosum
  - target: Hypotonia
  - target: Spastic tetraplegia
  - target: Lower limb spasticity
  - target: Seizures
  - target: Dystonia
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "This phenotype was completely rescued upon reintroduction of a cDNA construct (pIRES2-EGFP) into the Bcl11b mutant hippocampus containing either wild-type BCL11B (human) or Bcl11b (murine), but not by an equimolar amount of cDNA bearing the mutation as identified in Patient A:II-3 (Fig. 3 and Supplementary Fig. 3)."
    explanation: Mouse hippocampal progenitor proliferation depends on BCL11B and is not rescued by a patient allele.
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Notably, all of them are affected by global developmental delay with speech impairment and intellectual disability; however, none displayed overt clinical signs of immune deficiency."
    explanation: Fully penetrant neurodevelopmental phenotype across a 13-patient cohort.
  - reference: PMID:28424591
    reference_title: "Bcl11b-A Critical Neurodevelopmental Transcription Factor-Roles in Health and Disease."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Bcl11b is a fundamental transcription factor in fetal development, with important roles for the differentiation and development of various neuronal subtypes in the central nervous system (CNS)."
    explanation: Review synthesizing the neurodevelopmental roles of Bcl11b that underlie this node.
- name: Abnormal Cranial Suture and Craniofacial Development
  biological_scale: TISSUE
  description: >
    BCL11B maintains cranial suture patency and craniofacial cartilage patterning.
    A knock-in mouse carrying the human p.R3S variant develops coronal and other
    suture synostoses, and bcl11ba knockdown in zebrafish perturbs head cartilage and
    widens the interorbital distance.
  biological_processes:
  - preferred_term: cranial suture morphogenesis
    term:
      id: GO:0060363
      label: cranial suture morphogenesis
    modifier: ABNORMAL
  downstream:
  - target: Craniosynostosis
  - target: Wormian bones
  - target: Facial dysmorphism
  evidence:
  - reference: PMID:31067316
    reference_title: "A de novo substitution in BCL11B leads to loss of interaction with transcriptional complexes and craniosynostosis."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We generated a mouse model of the BCL11B p.R3S substitution using a CRISPR-Cas9-based approach, and we report herein that these mice exhibit craniosynostosis of the coronal suture, as well as other cranial sutures."
    explanation: Knock-in mouse recapitulating craniosynostosis from a human BCL11B variant.
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Knockdown of bcl11ba in zebrafish also reproduced other developmental abnormalities that were present in the patient, including craniofacial abnormalities and perturbation of the cartilagenous structures in the head (Fig. 2F)."
    explanation: Zebrafish knockdown reproduces the patient's craniofacial abnormalities.
- name: Abnormal Odontogenesis
  biological_scale: TISSUE
  description: >
    Bcl11b is required for tooth development in mice. Patients show natal teeth
    (index IMD49 patient) and small teeth, oligodontia or enamel defects.
  biological_processes:
  - preferred_term: odontogenesis
    term:
      id: GO:0042476
      label: odontogenesis
    modifier: ABNORMAL
  downstream:
  - target: Natal teeth
  - target: Dental anomalies
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: BACKGROUND
    snippet: "Biallelic loss of Bcl11b leads to perinatal lethality in mice, accompanied by defects in the development of the CNS (Arlotta et al., 2005; Simon et al., 2012), the epidermis (Golonzhka et al., 2009a), the teeth (Golonzhka et al., 2009b), as well as in the development and maintenance of the T cell lineage (Wakabayashi et al., 2003)."
    explanation: >-
      Introduction of a human cohort paper summarizing mouse knockout data that
      establishes BCL11B roles in tooth and epidermal development.
- name: Abnormal Epidermal Development
  biological_scale: TISSUE
  description: >
    Bcl11b is required for epidermal development in mice. The index IMD49 patient had
    erythematous psoriasiform dermatitis, and congenital erosive dermatitis occurred
    in one patient of the first IDDSFTA cohort.
  biological_processes:
  - preferred_term: epidermis development
    term:
      id: GO:0008544
      label: epidermis development
    modifier: ABNORMAL
  downstream:
  - target: Psoriasiform dermatitis
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: BACKGROUND
    snippet: "Biallelic loss of Bcl11b leads to perinatal lethality in mice, accompanied by defects in the development of the CNS (Arlotta et al., 2005; Simon et al., 2012), the epidermis (Golonzhka et al., 2009a), the teeth (Golonzhka et al., 2009b), as well as in the development and maintenance of the T cell lineage (Wakabayashi et al., 2003)."
    explanation: Background summary of the mouse epidermal phenotype of Bcl11b loss.
- name: Exacerbated Type 2 Helper T-Cell Responses
  biological_scale: ORGANISM
  description: >
    About half of reported patients have allergic disease (eosinophilia, allergies,
    asthma, atopic dermatitis). The proposed mechanism is loss of BCL11B's
    repressive control of Th2 differentiation, which has not been demonstrated in
    patient cells. It is not explained by ILC2s, which normally drive type 2
    inflammation but are reduced in these patients; the Lessel cohort authors
    suggest that exacerbated Th2 immunity together with the lack of ILC2-mediated
    epithelial repair may contribute to asthma.
  biological_processes:
  - preferred_term: T-helper 2 cell differentiation
    term:
      id: GO:0045064
      label: T-helper 2 cell differentiation
    modifier: INCREASED
  downstream:
  - target: Increased eosinophil count
  - target: Allergy
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In agreement with the previously reported repressive function of BCL11B on Th2 differentiation (Califano et al., 2014), exacerbated Th2 responses were clinically recognized in five patients, including two with asthma (Table 1 and Supplementary Table 2)."
    explanation: >-
      Clinical Th2 exacerbation in five cohort patients, interpreted by the authors
      in light of BCL11B's known repression of Th2 differentiation (a mouse finding
      they cite, not one they tested).
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eight patients showed exacerbated type 2 responses, namely eosinophilia (4/10) and allergies or asthma (7/12) (Fig. 1, Table 1 and Supplementary material)."
    explanation: Frequency of type 2 manifestations in the cohort.
  - reference: PMID:34887873
    reference_title: "A Novel Germline Heterozygous BCL11B Variant Causing Severe Atopic Disease and Immune Dysregulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Germline heterozygous variants are associated with a spectrum of clinical disorders, including severe combined immunodeficiency as well as neurological, craniofacial, and dermal defects. Of these individuals, ~50% present with severe allergic disease."
    explanation: >-
      The abstract's framing sentence summarizing previously published BCL11B
      patients, not this report's own finding.
  - reference: PMID:34887873
    reference_title: "A Novel Germline Heterozygous BCL11B Variant Causing Severe Atopic Disease and Immune Dysregulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Based on these data, we classify germline BCL11B-dependent atopic disease as a novel primary atopic disorder."
    explanation: Classification of BCL11B atopic disease as a primary atopic disorder.
phenotypes:
- name: Severe combined immunodeficiency
  category: Immunological
  description: >-
    Leaky T-B+NK+ SCID detected at birth by TREC newborn screening in the index
    IMD49 patient; the defining feature of IMD49 and absent from the IDDSFTA
    presentation.
  phenotype_term:
    preferred_term: Severe combined immunodeficiency
    term:
      id: HP:0004430
      label: Severe combined immunodeficiency
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The infant had \"leaky\" SCID (i.e., a form of SCID in which a minimal degree of immune function is preserved), as well as craniofacial and dermal abnormalities and the absence of a corpus callosum; his immune deficit was fully corrected by hematopoietic stem-cell transplantation."
    explanation: Clinical description of leaky SCID in the index patient.
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Immunologic studies revealed a T-B+NK+ phenotype, with no naive CD4+ helper T cells, an impaired proliferative response to phytohe-magglutinin (Table 1), and no maternal engraftment."
    explanation: Immunophenotype of the SCID.
- name: Absent T cell receptor excision circles
  category: Immunological
  phenotype_term:
    preferred_term: Absent T cell receptor excision circles
    term:
      id: HP:0031545
      label: Abnormally low T cell receptor excision circle level
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Screening revealed profound T-cell lymphopenia and no detectable TRECs (Table 1)."
    explanation: Undetectable TRECs on newborn screening.
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Concerning the immune system, the individual bearing a missense mutation (Patient E:II-1) had low T cell receptor excision circles at birth, though T cell measurements at later time points revealed T cell counts close to standard values."
    explanation: Low TRECs at birth in the zinc-finger missense patient of the IDDSFTA cohort.
- name: T lymphopenia
  category: Immunological
  phenotype_term:
    preferred_term: T lymphopenia
    term:
      id: HP:0005403
      label: Decreased total T cell count
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Screening revealed profound T-cell lymphopenia and no detectable TRECs (Table 1)."
    explanation: Profound T-cell lymphopenia in the index patient.
- name: Decreased naive CD4+ T cells
  category: Immunological
  phenotype_term:
    preferred_term: Decreased naive CD4+ T cells
    term:
      id: HP:0410378
      label: Decreased naive CD4+ T cell proportion
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Immunologic studies revealed a T-B+NK+ phenotype, with no naive CD4+ helper T cells, an impaired proliferative response to phytohe-magglutinin (Table 1), and no maternal engraftment."
    explanation: Absent naive CD4+ T cells in the index patient.
  - reference: PMID:37860968
    reference_title: "Clinico-biological refinement of BCL11B-related disorder and identification of an episignature: A series of 20 unreported individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We refine the intricacies of T cell compartment alterations of BCL11B-RD, revealing decreased levels naive CD4+ T cells and recent thymic emigrants while concurrently observing an elevated proportion of effector-memory expressing CD45RA CD8+ T cells (TEMRA)."
    explanation: Reduced naive CD4+ T cells across a 20-patient series.
- name: Impaired T-cell proliferation to phytohemagglutinin
  category: Immunological
  phenotype_term:
    preferred_term: Impaired T-cell proliferation to phytohemagglutinin
    term:
      id: HP:0025834
      label: Impaired phytohemagglutinin-induced T lymphocyte transformation
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Immunologic studies revealed a T-B+NK+ phenotype, with no naive CD4+ helper T cells, an impaired proliferative response to phytohe-magglutinin (Table 1), and no maternal engraftment."
    explanation: Impaired PHA proliferation in the index patient.
- name: Decreased recent thymic emigrant CD4+ T cells
  category: Immunological
  subtype: IDDSFTA
  phenotype_term:
    preferred_term: Decreased recent thymic emigrant CD4+ T cells
    term:
      id: HP:0025839
      label: Decreased RTE CD4+ T cell proportion
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The traits accounting for the differences in the T cell compartment between healthy donors and patients with mutations in BCL11B can be traced to: (i) an abnormally low percentage of CD4+ recent thymic emigrants (Fig. 4B)"
    explanation: Reduced recent thymic emigrants in IDDSFTA patients.
  - reference: PMID:37860968
    reference_title: "Clinico-biological refinement of BCL11B-related disorder and identification of an episignature: A series of 20 unreported individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We refine the intricacies of T cell compartment alterations of BCL11B-RD, revealing decreased levels naive CD4+ T cells and recent thymic emigrants while concurrently observing an elevated proportion of effector-memory expressing CD45RA CD8+ T cells (TEMRA)."
    explanation: Replication in an independent series.
- name: Increased gamma-delta T cell proportion
  category: Immunological
  subtype: IDDSFTA
  phenotype_term:
    preferred_term: Increased gamma-delta T cell proportion
    term:
      id: HP:0500270
      label: Increased gamma-delta T cell proportion
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "(ii) an overrepresentation of cells of the Tγδ lineage and TCR Vδ1 bias in detriment of the most common Vδ2γ 9 chains (Fig. 4D)"
    explanation: Expanded gamma-delta T cells in IDDSFTA patients.
- name: Intellectual disability
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Notably, all of them are affected by global developmental delay with speech impairment and intellectual disability; however, none displayed overt clinical signs of immune deficiency."
    explanation: >-
      13/13 in the IDDSFTA cohort. Banded VERY_FREQUENT rather than OBLIGATE
      because a later 20-patient series describes the disorder as occurring with
      or without intellectual disability (PMID:37860968).
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, he has intellectual impairment, with spastic quadriplegia and seizures."
    explanation: Intellectual impairment in the index IMD49 patient after transplantation.
- name: Global developmental delay
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Notably, all of them are affected by global developmental delay with speech impairment and intellectual disability; however, none displayed overt clinical signs of immune deficiency."
    explanation: >-
      13/13 in this cohort. Banded VERY_FREQUENT rather than OBLIGATE because an
      isolated-craniosynostosis patient without systemic findings has been
      reported (PMID:37337996).
- name: Delayed speech and language development
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Speech impairment
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We studied 13 patients affected by global developmental delay and intellectual disability with speech impairment."
    explanation: >-
      13/13 in this cohort. Banded VERY_FREQUENT rather than OBLIGATE because an
      isolated-craniosynostosis patient without systemic findings has been
      reported (PMID:37337996).
- name: Autistic behavior
  category: Neurological
  frequency: FREQUENT
  subtype: IDDSFTA
  phenotype_term:
    preferred_term: Autistic features
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Autistic features were observed in four patients."
    explanation: 4/13 = 31%, in the FREQUENT band (30-79%).
- name: Agenesis of corpus callosum
  category: Neurological
  phenotype_term:
    preferred_term: Agenesis of corpus callosum
    term:
      id: HP:0001274
      label: Agenesis of corpus callosum
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Imaging (not shown) revealed wormian skull bones, mild pulmonary artery stenosis, and the absence of a corpus callosum."
    explanation: Callosal agenesis in the index IMD49 patient.
  - reference: PMID:32659295
    reference_title: "BCL11B-related disorder in two canadian children: Expanding the clinical phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She also had dysgenesis of corpus callosum and dilatation of the frontal horns of lateral ventricles, a brain anomaly that has been previously reported in only one other patient."
    explanation: Callosal dysgenesis in a second, non-SCID patient.
- name: Hypotonia
  category: Neurological
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormal features (Fig. 1A) were accompanied by neonatal teeth, hypotonia, an umbilical hernia, and erythematous psoriaform dermatitis that was responsive to treatment with topical flucinolone."
    explanation: Neonatal hypotonia in the index patient.
- name: Spastic tetraplegia
  category: Neurological
  phenotype_term:
    preferred_term: Spastic quadriplegia
    term:
      id: HP:0002510
      label: Spastic tetraplegia
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, he has intellectual impairment, with spastic quadriplegia and seizures."
    explanation: Spastic quadriplegia in the index IMD49 patient.
- name: Lower limb spasticity
  category: Neurological
  phenotype_term:
    preferred_term: Lower limb spasticity
    term:
      id: HP:0002061
      label: Lower limb spasticity
  evidence:
  - reference: PMID:32659295
    reference_title: "BCL11B-related disorder in two canadian children: Expanding the clinical phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The second patient had developmental delay, dysmorphic features, spasticity in lower limbs and dental anomalies."
    explanation: Lower-limb spasticity in a non-SCID patient.
- name: Seizures
  category: Neurological
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, he has intellectual impairment, with spastic quadriplegia and seizures."
    explanation: Seizures in the index IMD49 patient.
- name: Dystonia
  category: Neurological
  phenotype_term:
    preferred_term: Generalized dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:38801144
    reference_title: "BCL11B-Related Dystonia: Further Evidence of an Emerging Cause of Childhood-Onset Generalized Dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recent case reports suggested that a complex movement disorder (MD) including spasticity and dystonia can be part of the phenotypic spectrum."
    explanation: Movement disorders reported across several BCL11B case reports.
  - reference: PMID:38801144
    reference_title: "BCL11B-Related Dystonia: Further Evidence of an Emerging Cause of Childhood-Onset Generalized Dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we report on a young girl with childhood‐onset generalized dystonia and ID carrying a de novo, likely pathogenic BCL11B variant."
    explanation: Case report of progressive generalized dystonia.
- name: Craniosynostosis
  category: Skeletal
  phenotype_term:
    preferred_term: Craniosynostosis
    term:
      id: HP:0001363
      label: Craniosynostosis
  evidence:
  - reference: PMID:40033098
    reference_title: "BCL11B-related disease: a single phenotypic entity?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Furthermore, we describe four new patients, all of whom presented with CRS, thus expanding the phenotype of BRD and highlighting CRS as an important diagnostic clue."
    explanation: Craniosynostosis in four additional patients.
  - reference: PMID:37337996
    reference_title: "Further validation of craniosynostosis as a part of phenotypic spectrum of BCL11B-related BAFopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Notably, craniosynostosis of variable degree was seen in all three individuals."
    explanation: Craniosynostosis in three further patients with exon 4 frameshift variants.
  - reference: PMID:31067316
    reference_title: "A de novo substitution in BCL11B leads to loss of interaction with transcriptional complexes and craniosynostosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using whole-genome sequencing, we identified a novel, de novo variant in BCL11B, c.7C>A, encoding an R3S substitution (p.R3S), in a male patient with coronal suture synostosis."
    explanation: Coronal synostosis in a patient with an N-terminal missense variant.
- name: Wormian bones
  category: Skeletal
  phenotype_term:
    preferred_term: Wormian bones
    term:
      id: HP:0002645
      label: Wormian bones
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Imaging (not shown) revealed wormian skull bones, mild pulmonary artery stenosis, and the absence of a corpus callosum."
    explanation: Wormian bones in the index IMD49 patient.
- name: Facial dysmorphism
  category: Craniofacial
  phenotype_term:
    preferred_term: Facial dysmorphism
    term:
      id: HP:0001999
      label: Abnormal facial shape
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Partially overlapping facial dysmorphisms were observed in all patients."
    explanation: Facial dysmorphism in all 13 patients.
  - reference: PMID:37860968
    reference_title: "Clinico-biological refinement of BCL11B-related disorder and identification of an episignature: A series of 20 unreported individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our findings unveil rarely documented clinical manifestations, notably including Rubinstein-Taybi-like facial features, craniosynostosis, and autoimmune disorders, all manifesting within the realm of BCL11B-RD."
    explanation: Rubinstein-Taybi-like facial features in a further series.
- name: Natal teeth
  category: Dental
  phenotype_term:
    preferred_term: Neonatal teeth
    term:
      id: HP:0000695
      label: Natal tooth
  notes: >-
    HPO has no separate neonatal-tooth class; HP:0000695 Natal tooth lists
    "Neonatal teeth" as a synonym and its definition covers teeth erupting within
    the first month of life.
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormal features (Fig. 1A) were accompanied by neonatal teeth, hypotonia, an umbilical hernia, and erythematous psoriaform dermatitis that was responsive to treatment with topical flucinolone."
    explanation: Neonatal teeth in the index patient.
- name: Dental anomalies
  category: Dental
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Small teeth, oligodontia or enamel defects
    term:
      id: HP:0000164
      label: Abnormality of the dentition
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Small teeth, oligodontia and/or enamel defects were present in five patients."
    explanation: Dental anomalies in 5/13 patients (38%, FREQUENT band 30-79%), reported jointly.
- name: Psoriasiform dermatitis
  category: Dermatological
  phenotype_term:
    preferred_term: Erythematous psoriasiform dermatitis
    term:
      id: HP:0003765
      label: Psoriasiform dermatitis
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormal features (Fig. 1A) were accompanied by neonatal teeth, hypotonia, an umbilical hernia, and erythematous psoriaform dermatitis that was responsive to treatment with topical flucinolone."
    explanation: Psoriasiform dermatitis in the index patient.
- name: Abnormality of refraction
  category: Ophthalmological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Refractive error
    term:
      id: HP:0000539
      label: Abnormality of refraction
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Refractive error was observed in five patients."
    explanation: 5/13 = 38%, in the FREQUENT band (30-79%).
- name: Umbilical hernia
  category: Gastrointestinal
  phenotype_term:
    preferred_term: Umbilical hernia
    term:
      id: HP:0001537
      label: Umbilical hernia
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormal features (Fig. 1A) were accompanied by neonatal teeth, hypotonia, an umbilical hernia, and erythematous psoriaform dermatitis that was responsive to treatment with topical flucinolone."
    explanation: Umbilical hernia in the index patient.
- name: Pulmonary artery stenosis
  category: Cardiovascular
  phenotype_term:
    preferred_term: Mild pulmonary artery stenosis
    term:
      id: HP:0004415
      label: Pulmonary artery stenosis
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Imaging (not shown) revealed wormian skull bones, mild pulmonary artery stenosis, and the absence of a corpus callosum."
    explanation: Pulmonary artery stenosis in the index patient.
- name: Increased eosinophil count
  category: Immunological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Eosinophilia
    term:
      id: HP:0001880
      label: Increased total eosinophil count
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eight patients showed exacerbated type 2 responses, namely eosinophilia (4/10) and allergies or asthma (7/12) (Fig. 1, Table 1 and Supplementary material)."
    explanation: Eosinophilia in 4/10 tested patients = 40%, in the FREQUENT band (30-79%).
- name: Allergy
  category: Immunological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Allergies or asthma
    term:
      id: HP:0012393
      label: Allergy
  evidence:
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eight patients showed exacerbated type 2 responses, namely eosinophilia (4/10) and allergies or asthma (7/12) (Fig. 1, Table 1 and Supplementary material)."
    explanation: Allergies or asthma in 7/12 patients = 58%, in the FREQUENT band (30-79%).
  - reference: PMID:34887873
    reference_title: "A Novel Germline Heterozygous BCL11B Variant Causing Severe Atopic Disease and Immune Dysregulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Germline heterozygous variants are associated with a spectrum of clinical disorders, including severe combined immunodeficiency as well as neurological, craniofacial, and dermal defects. Of these individuals, ~50% present with severe allergic disease."
    explanation: >-
      About half of previously reported patients have severe allergic disease
      (framing sentence summarizing earlier reports).
- name: Autoimmunity
  category: Immunological
  phenotype_term:
    preferred_term: Autoimmune disorders
    term:
      id: HP:0002960
      label: Autoimmunity
  notes: >-
    Deliberately not connected to a mechanism node. The only source reports
    autoimmune disorders as a rarely documented manifestation and proposes no
    mechanism; the reduced thymic output is a plausible but unstated link.
  evidence:
  - reference: PMID:37860968
    reference_title: "Clinico-biological refinement of BCL11B-related disorder and identification of an episignature: A series of 20 unreported individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our findings unveil rarely documented clinical manifestations, notably including Rubinstein-Taybi-like facial features, craniosynostosis, and autoimmune disorders, all manifesting within the realm of BCL11B-RD."
    explanation: Autoimmune disorders reported in a 20-patient series.
diagnosis:
- name: TREC-Based Newborn Screening
  description: >-
    The SCID presentation is detectable at birth by quantification of T-cell
    receptor excision circles on the newborn dried blood spot; the index IMD49
    patient had no detectable TRECs and was identified and transplanted before any
    infection. Low TRECs at birth were also recorded in a zinc-finger missense
    patient of the IDDSFTA cohort whose later T-cell counts were near normal, so a
    low TREC result does not by itself separate the two presentations.
  diagnosis_term:
    preferred_term: TREC newborn screening
    term:
      id: NCIT:C81178
      label: Newborn Screening
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Newborn screening facilitated the identification and treatment of a previously unknown cause of human SCID."
    explanation: TREC newborn screening identified the index IMD49 patient.
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SCID was detected in a newborn before the onset of infections by means of screening of T-cell-receptor excision circles, a biomarker for thymic output."
    explanation: Detection by TREC screening before infections.
- name: BCL11B Sequencing and Copy-Number Analysis
  description: >-
    Diagnosis is molecular: heterozygous BCL11B variants have been found by trio
    exome sequencing and genome sequencing. Deletions of 14q32.2 that include
    BCL11B also cause the disorder, so targeted copy-number analysis is advised when
    sequencing is negative and the disorder is suspected.
  diagnosis_term:
    preferred_term: exome or genome sequencing
    term:
      id: NCIT:C101295
      label: Whole Exome Sequencing
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Exome sequencing revealed a heterozygous de novo missense mutation, p.N441K, in BCL11B."
    explanation: Trio exome sequencing established the diagnosis in the index patient.
  - reference: PMID:29985992
    reference_title: "BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using massively parallel sequencing we identified 13 patients bearing heterozygous germline alterations in BCL11B."
    explanation: Massively parallel sequencing identified the IDDSFTA cohort.
  - reference: PMID:40033098
    reference_title: "BCL11B-related disease: a single phenotypic entity?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Finally, we show that BCL11B has been underappreciated as a contributor to the phenotype resulting from 14q32 microdeletion and that where BRD is suspected, targeted copy number analysis should be undertaken after negative sequencing results."
    explanation: Recommends copy-number analysis after negative sequencing.
- name: BCL11B DNA Methylation Episignature
  description: >-
    Peripheral blood DNA methylation profiling identifies a BCL11B-specific
    episignature that distinguishes affected individuals from controls and from
    other neurodevelopmental disorders with established episignatures, and can be
    used to reclassify BCL11B variants of uncertain significance.
  diagnosis_term:
    preferred_term: genome-wide DNA methylation episignature analysis
    term:
      id: NCIT:C63328
      label: DNA Methylation Analysis
  evidence:
  - reference: PMID:37860968
    reference_title: "Clinico-biological refinement of BCL11B-related disorder and identification of an episignature: A series of 20 unreported individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Finally, a distinct DNA methylation episignature exclusive to BCL11B-RD is unveiled."
    explanation: Identification of the episignature.
  - reference: PMID:37860968
    reference_title: "Clinico-biological refinement of BCL11B-related disorder and identification of an episignature: A series of 20 unreported individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Moreover, the identification of a unique DNA methylation episignature offers a valuable diagnosis tool for BCL11B-RD, thereby facilitating routine clinical practice by empowering physicians to reevaluate variants of uncertain significance within the BCL11B gene."
    explanation: States the diagnostic use of the episignature for variant reclassification.
treatments:
- name: Hematopoietic Stem Cell Transplantation
  description: >
    Allogeneic HSCT (a second transplant after conditioning with busulfan,
    fludarabine and antithymocyte globulin, following failed engraftment of the
    first) gave full T-cell engraftment, normal PHA proliferation, a normal
    T-cell-receptor repertoire and protective vaccine responses in the index IMD49
    patient. It does not correct the neurodevelopmental disability.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: allogeneic hematopoietic stem cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  target_mechanisms:
  - target: Arrest of T-Lineage Commitment and Development
    description: Donor-derived hematopoiesis supplies BCL11B-sufficient T-lineage progenitors.
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "By 2 years of age, the patient no longer required any medication and had protective vaccine responses; engraftment has remained stable."
    explanation: Durable immune reconstitution after HSCT.
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This was critical for our patient, who, despite having substantial developmental abnormalities outside the hematopoietic system, had full hematopoietic reconstitution after stem-cell transplantation."
    explanation: Immune correction despite persistent non-hematopoietic abnormalities.
- name: Antimicrobial Prophylaxis and Immunoglobulin Replacement
  description: >
    Pre-transplant supportive care for the SCID presentation: anti-infective
    prophylaxis and intravenous immune globulin.
  treatment_term:
    preferred_term: anti-infective prophylaxis and intravenous immune globulin
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_mechanisms:
  - target: Severe combined immunodeficiency
    description: Prevents infection while T-cell immunity is absent.
  evidence:
  - reference: PMID:27959755
    reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The infant received antiinfective prophylaxis and intravenous immune globulin."
    explanation: Supportive care given before transplantation.
animal_models:
- name: bcl11ba morphant zebrafish
  species: Zebrafish
  genotype: bcl11ba antisense morpholino knockdown, with or without ectopic human BCL11B p.N441K
  publication: PMID:27959755
  description: >
    Morpholino knockdown of the zebrafish BCL11B orthologue bcl11ba, and ectopic
    expression of the patient's p.N441K allele, block lck:GFP T-progenitor
    development, perturb head cartilage, widen interorbital distance and displace
    hematopoietic progenitors; wild-type but not mutant human BCL11B rescues.
  modeled_mechanisms:
  - target: Arrest of T-Lineage Commitment and Development
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: Knockdown or mutant expression blocks T-progenitor development, rescued by wild-type human BCL11B.
    limitations: >-
      Transient morpholino knockdown in embryos rather than a stable heterozygous
      allele; embryonic thymus seeding rather than postnatal human thymopoiesis.
    evidence:
    - reference: PMID:27959755
      reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Indeed, although re-expression of wild-type human BCL11B protein restored T-cell development and corrected the craniofacial abnormalities associated with its loss, human p.N441K BCL11B failed to do so (Fig. 3D)."
      explanation: Rescue experiment establishing the model's specificity for the T-lineage defect.
  - target: Abnormal Cranial Suture and Craniofacial Development
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: Head cartilage patterning and interorbital distance are altered.
    limitations: >-
      Zebrafish embryonic cartilage patterning is not cranial suture biology; the
      model does not address craniosynostosis.
    evidence:
    - reference: PMID:27959755
      reference_title: "Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Knockdown of bcl11ba in zebrafish also reproduced other developmental abnormalities that were present in the patient, including craniofacial abnormalities and perturbation of the cartilagenous structures in the head (Fig. 2F)."
      explanation: Craniofacial phenotype in the morphants.
- name: Bcl11b p.R3S knock-in mouse
  species: Mouse
  genotype: Bcl11b p.R3S (CRISPR-Cas9 knock-in)
  publication: PMID:31067316
  description: >
    Mouse carrying the human craniosynostosis BCL11B p.R3S substitution, which
    weakens binding to NuRD and PRC2; it develops coronal and other suture
    synostoses.
  modeled_mechanisms:
  - target: Abnormal Cranial Suture and Craniofacial Development
    relationship: RECAPITULATES
    fidelity: HIGH
    description: The knock-in reproduces coronal craniosynostosis seen in the patient.
    evidence:
    - reference: PMID:31067316
      reference_title: "A de novo substitution in BCL11B leads to loss of interaction with transcriptional complexes and craniosynostosis."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We generated a mouse model of the BCL11B p.R3S substitution using a CRISPR-Cas9-based approach, and we report herein that these mice exhibit craniosynostosis of the coronal suture, as well as other cranial sutures."
      explanation: Knock-in mouse craniosynostosis.

📚

References & Deep Research

References

PMID:27959755

Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B.

No top-level findings curated for this source.

PMID:29985992

BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells.

No top-level findings curated for this source.

PMID:37860968

Clinico-biological refinement of BCL11B-related disorder and identification of an episignature: A series of 20 unreported individuals.

No top-level findings curated for this source.

PMID:40033098

BCL11B-related disease: a single phenotypic entity?

No top-level findings curated for this source.

PMID:28424591

Bcl11b-A Critical Neurodevelopmental Transcription Factor-Roles in Health and Disease.

No top-level findings curated for this source.

PMID:35748970

Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.

No top-level findings curated for this source.

Deep Research

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Immunodeficiency 49 · 2026-09-28T13:06:05Z · View source

New entry for immunodeficiency 49 (MONDO:0014981), BCL11B deficiency, curated from PubMed primary literature (Punwani 2016 NEJM index SCID patient, Lessel 2018 Brain 13-patient IDDSFTA cohort, the 2024 Genet Med 20-patient series, the 2025 EJHG systematic review, craniosynostosis, dystonia, atopy and case-series reports, a 2017 Bcl11b neurodevelopment review, and the IUIS 2022 classification). All evidence snippets are exact quotes from these cached sources. Deep research: a Perplexity report (research/Immunodeficiency_49-deep-research-perplexity.md) is committed. The first run failed with a server disconnect; a rerun using a streaming request succeeded. It was screened as leads only. Of its two inline PMIDs, PMID:27959756 (given for Punwani 2016) is an unrelated NEJM HIV editorial (the correct PMID is 27959755), and PMID:38387286 (given for a 2024 BCL11B systematic review) is a chicken hepatocyte steatosis paper (the review it describes is PMID:40033098, 2025). Most HP CURIEs it proposes are wrong or nonexistent (for example HP:0002715 for SCID, HP:0002063 for spastic quadriplegia, HP:0005487 for corpus callosum agenesis, HP:0004411 for pulmonary artery stenosis, HP:0005342 unresolved), so none of its identifiers were used. Two leads were verified and added: the Bcl11b neurodevelopment review it cites by PMC link (PMID:28424591) as review-level support for the neurodevelopment node, and the mouse double-negative thymocyte arrest, quoted from the introduction of PMID:29985992. just preflight-dr could not run because the local MONDO build is absent. IDDSFTA (MONDO:0060763) is recorded as a has_subtypes row rather than a separate entry because both MONDO classes are heterozygous BCL11B disorders with shared mechanisms and the EJHG review found no significant distinction; the proposed genotype split is modelled as separate dominant-negative zinc-finger missense and haploinsufficiency root nodes. Pathograph: 12 pathophysiology nodes, 29 phenotypes, 26 causally connected (umbilical hernia, pulmonary artery stenosis and refractive error have no mechanistic source). Validated with just validate, count-verified-snippets (78/78), validate-terms, check-causal-targets, check-entity-refs, check-coarse-phenotypes, check-genereviews (no GeneReviews chapter) and validate-disorders.

Perplexity ▸

1. Disease Information

sonar-deep-research 19 citations 2026-09-28T13:21:07.595430

1. Disease Information

1.1 Definition and Core Clinical Concept

Immunodeficiency 49 (IMD49) is a Mendelian primary immunodeficiency defined by the presence of severe combined immunodeficiency with a characteristic immunophenotype of absent T lymphocytes, preserved B lymphocytes, and preserved natural killer (NK) cells, in association with neurodevelopmental impairment and craniofacial anomalies, caused by heterozygous germline pathogenic variants in BCL11B.[1][2][5][10] MedGen and MONDO classify IMD49 under MONDO:0014981 as “any primary immunodeficiency disease in which the cause of the disease is a mutation in the BCL11B gene,” emphasizing the gene-centric diagnostic concept.[2][5] The OMIM entry #617237, “Immunodeficiency 49, severe combined,” uses a number sign to denote that the phenotype is defined by causal mutation in BCL11B at 14q32.2, and describes it as autosomal dominant, reflecting the dominant-negative or haploinsufficient action of the variants identified to date.[1] Clinically, the original patient described by Punwani et al. presented with life-threatening infections, profound T-cell lymphopenia, and absent T-cell receptor excision circles (TRECs), fulfilling the criteria for SCID, alongside developmental delay, spastic quadriplegia, craniofacial dysmorphism, agenesis of the corpus callosum, skin abnormalities, and pulmonary artery stenosis.[10][16]

In the broader context of SCID nosology, IMD49 belongs to the subset of T− B+ NK+ SCID entities, similar in immunophenotype to conditions caused by biallelic IL7R or PTPRC/CD45 mutations (IMD104), but distinct in inheritance mode and syndromic features.[6][11][14] The National Organization for Rare Disorders (NORD) and related resources summarize IMD49 under descriptions such as “severe combined immunodeficiency, T cell-negative, B cell-positive, NK cell-positive, with intellectual disability, spasticity, and craniofacial abnormalities,” highlighting the integration of immune and developmental manifestations.[5][14] Abcam’s disease summary for BCL11B further distinguishes between a SCID phenotype with severe T-cell lymphopenia and multisystem anomalies, and a primarily developmental disorder with intellectual disability and speech delay, both caused by variants in the same gene.[15] Together, these resources support a view of IMD49 as the immunodeficiency-dominant end of a continuous spectrum of BCL11B-related disease.

1.2 Key Identifiers and Ontology Positioning

The principal identifiers for Immunodeficiency 49 include the OMIM phenotype number 617237, the MONDO identifier MONDO:0014981, and the MedGen concept C4310656; these entries consistently link the disease to BCL11B and describe its SCID phenotype.[1][2][5] The causal gene BCL11B itself is cataloged under OMIM 606558, HGNC:13222, and UniProtKB:Q9C0K0, with multiple synonym labels such as CTIP2, hRIT1, and “BAF chromatin remodeling complex subunit BCL11B,” reflecting its role as a transcription factor and chromatin complex component.[15][17][19] In disease vocabularies like the JAX Human Disease Vocabulary browser, IMD49 is listed among other numbered immunodeficiencies, reinforcing its classification within the expanding catalog of Mendelian primary immunodeficiencies.[3][6][8]

From an ontology perspective, IMD49 can be aligned with several formal terms. As a phenotype, “severe combined immunodeficiency” corresponds to the Human Phenotype Ontology (HPO) term HP:0002715, while “T-cell lymphopenia” is captured by HP:0005342 and “abnormal T-cell morphology” by HP:0005403.[6][11] Intellectual disability maps to HP:0001249, global developmental delay to HP:0001263, spastic quadriplegia to HP:0002063, and facial dysmorphism to HP:0001999.[10][12][13][15] The disease entity itself can be placed under MONDO:0005301 (severe combined immunodeficiency) as a subtype, with MONDO:0014981 specifying the BCL11B-associated form.[2][5] These ontology associations are important for machine-readable disease knowledge bases, enabling systematic integration of IMD49 into computational frameworks that link genes, phenotypes, and pathways.

1.3 Synonyms and Alternative Names

Several synonymous and alternative names have been used in the literature and databases to describe Immunodeficiency 49. MedGen lists the following composite label: “SCID, T cell-negative, B cell-positive, NK cell-positive, with intellectual disability, spasticity, and craniofacial abnormalities,” which effectively encapsulates the core clinical picture.[2] NORD and MONDO disease summaries use phrases such as “BCL11B primary immunodeficiency disease” and “primary immunodeficiency disease caused by mutation in BCL11B,” reflecting the gene-based nomenclature common in modern immunodeficiency classification.[5] OMIM and related catalogs use “Immunodeficiency 49, severe combined” and the abbreviation “IMD49,” consistent with the numbered naming scheme for Mendelian immunodeficiencies.[1][3][6][8]

In addition, BCL11B-related disease more broadly has been described under two formal OMIM entities: IMD49 (SCID form) and “Intellectual developmental disorder with dysmorphic facies, speech delay and T-cell abnormalities” (IDDSFTA; OMIM #618092).[12][13] The recent systematic review by Dalla Bernardina et al. (2024, PMID: 38387286) argues that these labels represent variable expressions of a single phenotypic entity, proposing the overarching term “BCL11B-related disease (BRD).”[12] For practical clinical and database applications, however, the term “Immunodeficiency 49” or “BCL11B-associated SCID” remains useful to denote the subset of patients in whom immunodeficiency is the dominant and life-threatening feature.

1.4 Nature of Available Information

Because Immunodeficiency 49 is exceedingly rare, current knowledge derives primarily from aggregated disease-level resources synthesizing a small number of individual case reports and cohort descriptions, rather than from large-scale epidemiologic datasets or electronic health record (EHR) analyses.[1][2][5][10][12][13] The founding NEJM case report by Punwani et al. provides detailed longitudinal clinical, immunologic, genetic, and functional data for a single affected individual, supplemented by experimental work in zebrafish and in vitro studies.[10][16] The later cohort described by Lessel et al. includes thirteen individuals with BCL11B variants, emphasizing neurodevelopmental features but reporting limited immunologic data.[13] The 2024 BCL11B-related disease review aggregates published cases and variant data, offering a systematic phenotype–genotype overview.[12]

Disease databases such as OMIM, MedGen, MONDO, and Orphanet have curated these primary sources to provide standardized entries.[1][2][5][17][19] ClinVar and ClinVarMiner list specific BCL11B variants submitted by diagnostic laboratories and researchers, often accompanied by clinical assertions of “pathogenic” or “likely pathogenic,” but these entries are themselves built from case-level data.[18] Given the small number of known patients, quantitative estimates of phenotype frequencies, penetrance, and prognosis are necessarily approximate and should be interpreted cautiously. Nevertheless, the convergence of findings across independent reports and model organism studies provides robust evidence that BCL11B loss-of-function and dominant-negative variants cause a distinctive combined immunologic and neurodevelopmental syndrome in humans.[9][10][12][13][16]

2. Etiology

2.1 Primary Causal Factors: Genetic Basis in BCL11B

The primary cause of Immunodeficiency 49 is heterozygous germline mutation in BCL11B, a gene encoding a C2H2 zinc finger transcription factor that functions as a component of the BAF (SWI/SNF) chromatin remodeling complex and as a critical regulator of T-cell and neuronal development.[1][9][10][12][17][19] OMIM #617237 explicitly assigns causality to heterozygous BCL11B mutations, and uses the number sign notation to indicate that the phenotype is defined by pathogenic variants in this specific gene.[1] MedGen and MONDO describe IMD49 as “any primary immunodeficiency disease in which the cause of the disease is a mutation in the BCL11B gene,” leaving open the possibility of multiple variant classes but emphasizing the gene-level etiology.[2][5]

The index case of IMD49 reported by Punwani et al. carried a de novo heterozygous missense variant, c.1323T>G (p.Asn441Lys, N441K) in BCL11B (NM_138576.3), not present in either parent, establishing a dominant mode of inheritance.[10][16] Functional analysis demonstrated that the mutant protein had dominant-negative activity, disrupting the DNA-binding capacity of wild-type BCL11B and abrogating its transcriptional regulatory functions in T-cell progenitors and other cell types.[10] Zebrafish models expressing the mutant human BCL11B recapitulated the patient’s immunologic and craniofacial abnormalities, whereas expression of wild-type human BCL11B rescued the phenotype in bcl11ba-deficient zebrafish, providing strong experimental evidence of causality.[10][16] Subsequent reports have identified additional heterozygous BCL11B variants—including frameshift, nonsense, and other missense changes—associated with neurodevelopmental disorders with or without immunodeficiency, supporting a broader BCL11B-related disease spectrum.[12][13][18]

The genetic etiology is, therefore, monogenic, with BCL11B variants acting as necessary and sufficient causes of the disease phenotype in affected individuals, subject to modifiers such as variant type, location within functional domains, and potential interactions with other regulatory factors. There is currently no evidence that environmental, infectious, or polygenic factors alone can produce a clinical picture indistinguishable from IMD49 in the absence of BCL11B mutation.

2.2 Genetic Risk Factors: Causal Variants and Susceptibility

In IMD49, the key genetic risk factors are the pathogenic BCL11B variants themselves, which function as causal lesions rather than mere susceptibility alleles. The index variant p.N441K resides in the central portion of the protein, in a region important for DNA binding and transcriptional regulation; its dominant-negative effect leads to broad disruption of BCL11B-controlled gene networks.[10][16] ClinVarMiner lists at least fourteen BCL11B variants reported as “likely pathogenic” for BCL11B-related conditions, including multiple frameshift mutations (e.g., c.1206del, p.Phe403fs; c.1535_1536del, p.Ala512fs; c.1582del, p.His528fs; c.1707del, p.Gly570fs; c.1742del, p.Gly581fs; c.2439_2452dup, p.His818fs; c.2448_2461del, p.Ser817fs; c.2474dup, p.Cys826fs; c.363dup, p.Asp122fs; c.908del, p.Pro303fs) and missense variants (e.g., c.2421C>G, p.Asn807Lys; c.2507G>A, p.Ser836Asn; c.2513A>G, p.Lys838Arg; c.785G>A, p.Arg262Gln).[18] These variants are typically absent or extremely rare in population databases such as gnomAD, supporting pathogenicity by extreme rarity and segregation data.

Lessel et al. reported thirteen individuals with heterozygous germline BCL11B variants, most of which led to protein truncation or haploinsufficiency; these patients exhibited global developmental delay, speech impairment, and intellectual disability, but no overt clinical immunodeficiency.[13] The 2024 review argues that truncating variants causing loss of one allele (haploinsufficiency) are more likely to produce neurodevelopmental-predominant phenotypes, whereas specific missense variants with dominant-negative effects—such as N441K—can lead to more severe multisystem syndromes including SCID.[12] From a genetic risk perspective, any loss-of-function or deleterious missense mutation in BCL11B appears capable of causing disease, with the precise phenotype depending on functional impact; there is no evidence of common susceptibility polymorphisms that modestly increase risk without causing disease.

Additional genetic factors, such as modifier genes or polygenic background, have not yet been systematically identified in IMD49, largely due to the small number of cases. However, because BCL11B operates within complex transcriptional networks that involve Notch signaling, TCF-1, and GATA3 in T-lineage commitment, it is plausible that variation in these pathways could modulate disease severity, although this remains speculative and unproven in humans.[9][10][12]

2.3 Environmental and Lifestyle Risk Factors

Given the monogenic, mostly de novo nature of IMD49, there are no established environmental or lifestyle factors that increase the risk of developing the disease in individuals without BCL11B mutation. The causal mutation arises spontaneously in the germline, typically during gametogenesis or early embryogenesis, and current data do not implicate parental exposures, infections, toxins, or occupational factors as triggers in a reproducible way.[10][12][16] Some general studies of de novo mutations suggest a modest association with advanced paternal age, reflecting increased replication cycles in spermatogenesis, but such associations have not been specifically evaluated for BCL11B variants and cannot be considered disease-specific risk factors.[12]

In affected individuals, environmental factors play a critical role in modulating disease expression, particularly regarding infection risk and severity. As with other SCID forms, exposure to common viral, bacterial, and fungal pathogens can precipitate severe, life-threatening infections due to the absence of functional T-cell immunity, and thus environmental management (e.g., protective isolation, avoidance of live vaccines, rigorous infection control) is essential.[11][14] However, these exposures do not contribute to disease causation per se; they act as triggers for clinical episodes in individuals whose immunodeficiency is genetically determined.

Lifestyle factors such as diet, smoking, alcohol consumption, and physical activity have not been studied in the context of IMD49, and given the typical early onset and severe developmental impairment, most patients are infants or young children for whom adult lifestyle risk factors are not directly relevant. Overall, environmental and lifestyle factors are best understood as modifiers of clinical course rather than etiologic agents.

2.4 Protective Factors and Gene–Environment Interactions

Specific genetic protective factors—variants that mitigate the impact of BCL11B mutations—have not been identified in IMD49, again reflecting the small case numbers and lack of systematic modifier studies.[12] It is plausible that redundancy and plasticity within developmental transcriptional networks might confer some resilience to partial BCL11B dysfunction, accounting for the variable expressivity observed among patients with different variants; for example, some individuals with truncating variants exhibit severe intellectual disability but retain sufficient T-cell function to avoid clinically overt immunodeficiency.[12][13] Nevertheless, such protective mechanisms remain hypothetical and have not been mapped to specific alleles.

Environmental protective factors are more clearly defined and correspond to standard measures used in SCID management. Early diagnosis through newborn SCID screening, followed by protective isolation, antimicrobial prophylaxis, and timely HSCT, can dramatically improve survival, effectively “protecting” patients from the most severe consequences of their immunodeficiency.[10][11][14][16] Avoidance of live attenuated vaccines, careful nutritional support, and intensive developmental therapies may also help prevent complications and optimize neurodevelopmental outcomes, though their protective effect is supportive rather than etiologic.

Gene–environment interactions in IMD49 are dominated by the interplay between genetic immunodeficiency and environmental pathogen exposure. The causal chain is straightforward: BCL11B mutation leads to impaired T-cell development; this causes profound cellular immune deficiency; environmental exposure to pathogens results in severe infections and related complications.[10][11][14] While this interaction is critical for clinical outcomes, it does not modify the underlying genetic cause. There is currently no evidence that environmental or epigenetic factors can significantly compensate for the transcriptional dysregulation caused by BCL11B variants or prevent the emergence of core neurological and craniofacial anomalies.

3. Phenotypes

3.1 Overview of Phenotypic Spectrum

The phenotypic spectrum of Immunodeficiency 49 encompasses immunologic, neurologic, craniofacial, dermatologic, and cardiovascular manifestations, reflecting the role of BCL11B in multiple organ systems. At the immunologic level, IMD49 presents as a form of SCID characterized by severe T-cell lymphopenia with preserved or near-normal B-cell and NK-cell counts, resulting in life-threatening infections, failure to thrive, and absent T-cell receptor excision circles on newborn screening.[2][5][10][11][14][15] Neurologically, affected individuals exhibit global developmental delay, intellectual disability, spasticity or spastic quadriplegia, and structural brain anomalies such as agenesis of the corpus callosum.[10][12][13][15] Craniofacial dysmorphism is a prominent feature, with abnormalities of midface structure, palate, and skull shape; cutaneous findings such as erythematous psoriasiform dermatitis have also been reported.[10][13][15] Cardiovascular anomalies, notably pulmonary artery stenosis, have been observed in at least one patient.[10][16]

The 2018 cohort described by Lessel et al. reveals that BCL11B mutations can cause a neurodevelopmental disorder with global developmental delay, speech impairment, and intellectual disability, often accompanied by dysmorphic facies and variable minor immunologic abnormalities, but without overt SCID.[13] The authors note that “none displayed overt clinical signs of immune deficiency,” suggesting that BCL11B’s developmental roles may be more sensitive to haploinsufficiency than its role in T-cell lineage commitment, at least for certain variant types.[13] The 2024 review integrates these findings and concludes that BCL11B-related disease represents a single phenotypic entity with variable expression of immune and neurodevelopmental features, depending on the nature of the variant.[12]

From an ontology perspective, these phenotypes correspond to multiple HPO terms. Severe combined immunodeficiency aligns with HP:0002715, T-cell lymphopenia with HP:0005342, absent naive CD4+ T cells with HP:0005403, recurrent infections with HP:0002719, global developmental delay with HP:0001263, intellectual disability with HP:0001249, spasticity with HP:0001257, spastic quadriplegia with HP:0002063, facial dysmorphism with HP:0001999, agenesis of corpus callosum with HP:0005487, pulmonary artery stenosis with HP:0004411, and erythematous skin rash with HP:0001058.[10][11][12][13][15] These ontology associations facilitate structured phenotyping in clinical and research settings.

3.2 Immunologic Phenotypes

The hallmark immunologic phenotype in IMD49 is SCID with a T− B+ NK+ immunophenotype. Punwani et al. report that their patient exhibited “severe T-cell lymphopenia, no detectable T-cell receptor excision circles, no naive helper CD4+ T-cells, and impaired T-cell proliferative response,” consistent with a profound defect in T-cell development.[10][15][16] Flow cytometry demonstrated near absence of CD3+ T cells, with preserved B cells and NK cells, matching the T− B+ NK+ pattern.[10] These features correspond to HPO terms such as T-cell lymphopenia (HP:0005342), decreased CD4+ T-cell count (HP:0005344), abnormal T-cell physiology (HP:0005403), and recurrent severe infections (HP:0002719).[11][14]

Clinically, patients present in early infancy with severe infections, including pneumonia, chronic diarrhea, failure to thrive, and opportunistic infections, similar to other SCID forms.[10][11][14] The absence of TRECs on newborn screening, a standard SCID detection method, may be the first indication of disease.[10][16] Laboratory abnormalities include lymphopenia, hypogammaglobulinemia due to defective T-cell help for B cells, and impaired T-cell proliferation in response to mitogens.[10][11][14] Importantly, the immunophenotype distinguishes IMD49 from other SCID subtypes such as T− B− NK+ SCID caused by RAG1/RAG2 mutations, or T− B+ NK− SCID caused by JAK3 mutations.[11] This distinction has implications for differential diagnosis and management.

In terms of quality of life, the immunologic phenotype has profound impact. Untreated SCID is uniformly fatal in early childhood due to overwhelming infections, and even with treatment, patients require rigorous infection control, prophylactic antimicrobials, and may experience repeated hospitalizations.[11][14] The burden on families is substantial, encompassing emotional stress, financial costs, and intensive caregiving demands. HSCT can restore immune function, but may entail risks of graft-versus-host disease, transplant-related mortality, and long-term complications.[10][11][14] For ontology-based disease modeling, these immunologic features can be tied to GO biological processes such as “T cell differentiation” (GO:0030217), “immune system process” (GO:0002376), and “adaptive immune response” (GO:0002250), and to cell ontology terms such as “T cell” (CL:0000084), “naive CD4-positive, alpha-beta T cell” (CL:0000895), and “hematopoietic stem cell” (CL:0000037).[9][10]

3.3 Neurodevelopmental and Neurological Phenotypes

Neurodevelopmental impairment is a defining feature of IMD49 and of BCL11B-related disease more broadly. The index SCID patient exhibited severe delayed psychomotor development, intellectual disability, and spastic quadriplegia, indicating widespread dysfunction of motor and cognitive circuits.[10][15][16] Brain imaging revealed agenesis of the corpus callosum and other structural anomalies, consistent with disrupted cortical connectivity and axon pathfinding.[10][16] These features can be mapped to HPO terms such as global developmental delay (HP:0001263), intellectual disability (HP:0001249), spastic quadriplegia (HP:0002063), and agenesis of corpus callosum (HP:0005487).

Lessel et al. describe thirteen patients with heterozygous BCL11B variants who all display “global developmental delay with speech impairment and intellectual disability,” often accompanied by behavioral issues and hypotonia, but without overt clinical immunodeficiency.[13] The authors note that structural brain anomalies, including corpus callosum abnormalities and cortical malformations, are common, though variably expressed.[13] The 2024 review synthesizes these data and argues that neurodevelopmental phenotypes are present across the entire spectrum of BCL11B-related disease, irrespective of SCID status, suggesting that BCL11B’s role in CNS development is highly dosage-sensitive.[12]

Mechanistically, these phenotypes reflect BCL11B’s critical function as a neurodevelopmental transcription factor. Murine studies show that Bcl11b is essential for differentiation of corticospinal motor neurons, striatal medium spiny neurons, and hippocampal granule cells; knockout mice display cortical layering defects, axon pathfinding abnormalities, striatal disorganization, and impaired adult hippocampal neurogenesis.[9] Simon et al. demonstrated that Bcl11b is required for specification and survival of adult-born hippocampal granule cells, linking it to learning and memory circuits.[9] These animal data align with human findings of intellectual disability and motor impairment, supporting a causal chain from BCL11B variant to disrupted transcriptional programs in CNS progenitors, to structural and functional brain anomalies, and ultimately to clinical neurodevelopmental deficits.[9][10][12][13]

The impact on quality of life is profound. Patients often require lifelong support with motor function, communication, and activities of daily living; many are non-verbal or have limited expressive language, and spasticity can severely restrict mobility.[10][13][15] Neurodevelopmental therapies—including physical, occupational, and speech therapy—are essential, but may only partially ameliorate deficits. In ontology terms, these features relate to GO processes such as “central nervous system development” (GO:0007417), “axon guidance” (GO:0007411), and “synapse organization” (GO:0050808), and to cell ontology terms such as “corticospinal neuron” (CL:0008105), “medium spiny neuron” (CL:0008033), and “hippocampal granule cell” (CL:0002605).[9][12]

3.4 Craniofacial, Dermatologic, and Cardiovascular Phenotypes

Craniofacial anomalies are a prominent component of IMD49. The index SCID patient displayed distinctive facial dysmorphism, including midface hypoplasia, abnormal nasal bridge, and other characteristic features.[10][16] Lessel et al. report that all patients with BCL11B variants in their cohort have dysmorphic facies, though with variable patterns, often involving high forehead, broad nasal bridge, and thin upper lip.[13] These features can be captured by HPO terms such as facial dysmorphism (HP:0001999), abnormality of the midface (HP:0000324), and abnormal palate morphology (HP:0000174), depending on the specific findings.[10][12][13]

Cutaneous manifestations have been described, particularly in the SCID case where the patient had erythematous psoriasiform dermatitis.[10][13] This can be mapped to HPO terms like erythematous rash (HP:0001058) and psoriasiform dermatitis (HP:0001033). Such skin findings may reflect BCL11B’s role in ectodermal development or immune regulation in the skin, though mechanisms are not fully elucidated.[10][12][13] Cardiovascular anomalies, notably pulmonary artery stenosis, were observed in the index case, suggesting that vascular development may also be perturbed.[10][16] This corresponds to HPO term pulmonary artery stenosis (HP:0004411).

These craniofacial and cardiovascular features have significant clinical implications. Craniofacial anomalies may affect feeding, speech, and airway management, increasing morbidity; pulmonary artery stenosis can lead to right ventricular outflow obstruction, decreased pulmonary blood flow, and heart failure if severe.[10] Dermatologic manifestations may cause discomfort, secondary infections, and social stigma. While less immediately life-threatening than SCID, they contribute substantially to overall disease burden and require multidisciplinary management involving craniofacial surgeons, dermatologists, and cardiologists.

From an anatomical ontology perspective, craniofacial anomalies involve UBERON structures such as “face” (UBERON:0001456), “palate” (UBERON:0001835), and “cranial vault” (UBERON:0010890). Cardiovascular anomalies involve “pulmonary artery” (UBERON:0001510) and related vascular structures. These features may be linked mechanistically to BCL11B’s role in neural crest-derived cell populations and in vomeronasal sensory neuron development, as suggested by murine data indicating that Bcl11b is critical for differentiation and structural organization of vomeronasal neurons, which influence craniofacial morphogenesis.[9]

3.5 Phenotype Onset, Severity, Progression, and Frequency

In IMD49, immunologic phenotypes typically present in the neonatal period or early infancy, often detected by newborn SCID screening via absent TRECs or by early severe infections.[10][11][14][16] Neurological and craniofacial phenotypes are congenital or apparent within the first months of life; motor delay and spasticity may become obvious as infants fail to achieve developmental milestones, while structural brain anomalies can be detected by neuroimaging early on.[10][12][13] Severity is generally high: SCID is life-threatening without HSCT, and neurodevelopmental impairment ranges from moderate to severe intellectual disability with major motor deficits.[10][13][15]

Symptom progression in the immunologic domain depends heavily on treatment. Without HSCT, infections become progressively more frequent and severe, leading to death in early childhood.[11][14] With successful HSCT, T-cell counts and function may normalize, reducing infection risk, though some residual immune abnormalities may persist.[10] Neurodevelopmental and craniofacial anomalies are largely non-progressive but remain static or improve slowly with therapy; they represent developmental malformations rather than degenerative processes.[9][10][12][13] Spasticity and motor impairment may be relatively stable but can result in secondary complications such as contractures and orthopedic deformities if not managed aggressively.

Frequency estimates for individual phenotypes are constrained by small sample size. In the SCID index case, all major features—SCID, intellectual disability, spastic quadriplegia, craniofacial anomalies, corpus callosum agenesis, skin rash, pulmonary artery stenosis—were present.[10][16] In the thirteen-patient cohort, global developmental delay, speech impairment, and intellectual disability were universal, whereas immunologic abnormalities were subclinical.[13] The 2024 review suggests that neurodevelopmental impairment and facial dysmorphism are nearly universal across reported BCL11B-related cases, while SCID appears in a minority, likely associated with specific dominant-negative variants.[12] Thus, one may provisionally assign frequencies of near 100% for global developmental delay and facial dysmorphism, high but variable frequencies for structural brain anomalies, and low to moderate frequencies for overt SCID, pending more data.

Quality of life impact is substantial across phenotypes. Severe immunodeficiency threatens survival and requires intensive medical management; neurodevelopmental impairment and spasticity impose lifelong functional disabilities; craniofacial anomalies and skin disease affect psychosocial well-being; and cardiovascular anomalies can limit exercise capacity and increase risk of cardiac events.[10][11][12][13][15] These impacts underscore the need for holistic, multidisciplinary care and for standardized assessment using tools such as the SF-36, EQ-5D, and PROMIS, although such instruments have not yet been applied systematically to IMD49.

4. Genetic and Molecular Information

4.1 Causal Gene: BCL11B and Its Functional Context

The causal gene for Immunodeficiency 49 is BCL11B (BAF Chromatin Remodelling Complex Subunit BCL11B), located on chromosome 14q32.2.[1][2][17][19] BCL11B encodes a C2H2 zinc finger transcription factor that binds to DNA and interacts with the BAF (SWI/SNF) chromatin remodeling complex, influencing gene expression across multiple developmental pathways.[9][17][19] Gene catalogs such as HGNC (HGNC:13222), OMIM (606558), and UniProtKB (Q9C0K0) list numerous synonyms, including CTIP2, CTIP-2, hRit1-alpha, SMARCM2, and “B cell CLL/lymphoma 11B,” reflecting its initial identification in lymphoid malignancies and its broader role in chromatin biology.[15][17][19]

In the immune system, BCL11B is essential for T-cell lineage commitment in the thymus. Murine studies show that Bcl11b is required for the transition from double-negative stage 2 (DN2) to DN3 thymocytes, and for suppression of alternative innate-like fates; Bcl11b-deficient thymocytes fail to upregulate T-cell receptor genes and adopt NK-like characteristics.[9] In the central nervous system, Bcl11b is expressed in layer V corticospinal motor neurons, striatal medium spiny neurons, hippocampal granule cells, and GABAergic interneurons across cortical layers; it plays key roles in axon pathfinding, neuronal specification, and adult hippocampal neurogenesis.[9] Bcl11b knockout mice die perinatally and exhibit widespread structural brain defects and immune failure, illustrating its indispensable role in development.[9]

These functions are mediated through BCL11B’s ability to bind DNA at specific sites and recruit chromatin remodeling complexes, thereby activating or repressing target genes in a context-dependent manner. Punwani et al. demonstrated that the N441K variant abolishes BCL11B’s DNA-binding capacity in human cells, leading to a dominant-negative effect that interferes with wild-type BCL11B function.[10] This disruption impairs transcriptional programs controlling hematopoietic stem cell migration into the thymus, thymocyte differentiation, and possibly neuronal and craniofacial development.[10][16]

Ontologically, BCL11B is associated with GO molecular function terms such as “DNA-binding transcription factor activity” (GO:0003700), “sequence-specific DNA binding” (GO:0043565), and “chromatin binding” (GO:0003682). Its biological process associations include “T cell differentiation” (GO:0030217), “neuron differentiation” (GO:0030182), “regulation of transcription, DNA-templated” (GO:0006355), and “central nervous system development” (GO:0007417).[9][10][12] These annotations are consistent with IMD49’s combined immunologic and neurodevelopmental phenotype.

4.2 Pathogenic Variants: Types, Classification, and Population Frequency

Pathogenic BCL11B variants associated with IMD49 and broader BCL11B-related disease include missense changes, frameshift and nonsense mutations, and potentially splice-site alterations. The index IMD49 variant, c.1323T>G (p.Asn441Lys, N441K), is a missense change in the central portion of the protein, identified as de novo and classified as pathogenic in ClinVar (SCV000297993).[10][16] Functional studies show that the N441K mutant protein exhibits dominant-negative activity, blocking DNA binding and impairing transcriptional regulation.[10] This variant is absent from population databases and from parental genomes, supporting its pathogenicity and de novo origin.[10][16]

ClinVarMiner lists fourteen BCL11B variants reported as “likely pathogenic,” many of which are frameshift mutations leading to premature truncation of the protein.[18] These include c.1206del (p.Phe403fs), c.1535_1536del (p.Ala512fs), c.1582del (p.His528fs), c.1707del (p.Gly570fs), c.1742del (p.Gly581fs), c.2439_2452dup (p.His818fs), c.2448_2461del (p.Ser817fs), c.2474dup (p.Cys826fs), c.363dup (p.Asp122fs), and c.908del (p.Pro303fs).[18] Several missense variants are also listed, such as c.2421C>G (p.Asn807Lys), c.2507G>A (p.Ser836Asn), c.2513A>G (p.Lys838Arg), and c.785G>A (p.Arg262Gln).[18] These variants have extremely low or absent frequencies in gnomAD, reinforcing their pathogenic status.[18]

Lessel et al. identify thirteen heterozygous BCL11B variants in patients with neurodevelopmental disorders, including frameshift, nonsense, and missense changes; many truncating variants are predicted to cause haploinsufficiency, while certain missense variants may alter specific functional domains.[13] The authors classify these variants as pathogenic based on segregation, de novo occurrence, and predicted protein impact.[13] The 2024 review integrates ClinVar and published data to provide an updated catalog of BCL11B variants, noting that most pathogenic variants are unique to individual families, consistent with de novo occurrence and extreme rarity.[12]

In terms of ACMG/AMP classification, N441K and the reported frameshift/nonsense variants meet criteria for “pathogenic” or “likely pathogenic” based on de novo status, functional evidence, predicted loss of function in a gene where LoF is a known disease mechanism, and absence from control databases.[10][12][13][18] Variant type appears to influence phenotype: dominant-negative missense variants such as N441K are associated with SCID and multisystem anomalies, whereas truncating variants causing haploinsufficiency may produce neurodevelopmental-predominant phenotypes with milder or subclinical immune abnormalities.[12][13] However, this genotype–phenotype correlation remains provisional due to limited case numbers.

All reported disease-causing BCL11B variants in IMD49 and related disorders are germline, affecting all tissues derived from the zygote.[10][12][13] Somatic BCL11B mutations are well-described in T-cell leukemias but are not relevant to IMD49.[17][19] Germline mosaicism has not been documented, though it remains a theoretical possibility in families with more than one affected child and unaffected parents; given the rarity of cases, such patterns have not emerged.[12]

4.3 Functional Consequences: Loss of Function, Dominant Negative, and Haploinsufficiency

Functional studies of BCL11B variants provide insight into disease mechanisms. Punwani et al. demonstrated that the N441K mutant protein lacks DNA-binding capacity and behaves as a dominant-negative: when co-expressed with wild-type BCL11B in human cells, it prevents wild-type from binding to target sites and from activating transcriptional programs required for T-cell development.[10] This dominant-negative action explains why a single heterozygous variant can cause severe SCID, despite the presence of one intact allele.[10][16]

Frameshift and nonsense variants, by contrast, are predicted to cause loss of function through nonsense-mediated decay or production of truncated proteins lacking essential domains. Lessel et al. argue that such variants lead to haploinsufficiency—insufficient levels of functional BCL11B protein—which disrupts neurodevelopmental processes but may spare T-cell development to some extent, resulting in neurodevelopmental disorders without clinically overt SCID.[13] The 2024 review supports this interpretation, proposing that variant type (dominant-negative vs. haploinsufficient) shapes the relative expression of immune and neurological phenotypes.[12]

Mechanistically, both dominant-negative and haploinsufficient effects converge on loss of BCL11B function at the transcriptional level. BCL11B regulates a network of target genes involved in hematopoietic stem cell homing, thymocyte differentiation, neuronal specification, and craniofacial morphogenesis; disruption of this network leads to the chain of pathogenic events described in the mechanism section.[9][10][12] The distinction lies in whether the mutant protein actively interferes with wild-type function (dominant-negative) or simply reduces overall dosage (haploinsufficiency).

Ontologically, these functional consequences can be captured by GO terms such as “negative regulation of transcription by RNA polymerase II” (GO:0000122) for dominant-negative effects, and “haploinsufficiency disease” as a conceptual category in MONDO and ClinGen. For precision variant annotation, integrating functional data, variant type, and structural information is essential to refine pathogenicity assessments and to predict phenotype severity in newly identified BCL11B variants.

4.4 Modifier Genes, Epigenetic Information, and Chromosomal Abnormalities

Modifier genes for IMD49 have not been definitively identified. However, given BCL11B’s integration into T-cell specification networks, genes such as NOTCH1, TCF7 (TCF-1), GATA3, and components of the BAF complex may theoretically modify disease expression.[9][10] For example, partial redundancy in chromatin remodeling complexes or compensation by other transcription factors might mitigate the impact of BCL11B haploinsufficiency in some developmental contexts.[9] In mice, interactions between Bcl11b and Fezf2 have been reported in corticospinal neuron development, suggesting that variation in Fezf2 could influence cortical phenotypes.[9] Human data on such modifiers in IMD49 are currently lacking.

Epigenetically, BCL11B itself is a chromatin-associated protein, and its dysfunction likely leads to altered DNA methylation and histone modification patterns at target loci. As a component of the BAF complex, BCL11B participates in ATP-dependent chromatin remodeling, influencing nucleosome positioning and accessibility.[9][17][19] DiseaseMeth and ENCODE have not yet provided IMD49-specific epigenomic profiles, but one can infer that loss of BCL11B function causes widespread epigenetic dysregulation in T-cell progenitors and neuronal precursors.[9][10][12] Such changes would fall under GO terms like “chromatin remodeling” (GO:0006338) and “epigenetic regulation of gene expression” (GO:0040029).

Chromosomal abnormalities involving BCL11B are known in somatic contexts—e.g., translocations in T-cell leukemia—but germline structural variants causing IMD49 have not been reported.[17][19] DECIPHER and related databases contain occasional copy number variants spanning 14q32.2, but these have not been conclusively linked to BCL11B-related SCID. The primary etiologic mechanism remains point mutations and small indels in the coding sequence.

5. Environmental Information

5.1 Environmental, Lifestyle, and Occupational Factors

As a monogenic primary immunodeficiency with predominantly de novo germline mutations, Immunodeficiency 49 is not known to be caused or strongly influenced by specific environmental toxins, radiation, pollution, occupational exposures, or lifestyle factors. The causal BCL11B variants arise spontaneously in the parental germline or early embryo, and current case reports do not identify consistent environmental antecedents.[10][12][16] Epidemiologic databases and toxicogenomics resources such as CTD and TOXNET have not linked environmental chemicals specifically to BCL11B mutation or IMD49.

Lifestyle factors such as smoking, diet, exercise, and alcohol consumption are irrelevant to disease causation in most cases, as patients are affected from birth or early infancy, before such behaviors could exert effects. Caregiver lifestyle may influence infection exposure or overall health environment, but these do not alter the genetic lesion. Occupational exposures similarly have limited relevance given the pediatric age of onset.

From a mechanistic standpoint, environmental factors may modulate disease course by influencing infection risk, nutritional status, and access to medical care, but they do not appear to interact with BCL11B at the molecular level in a way that changes disease susceptibility. Thus, environmental and lifestyle factors in IMD49 are best conceptualized as contextual modifiers of clinical outcomes rather than etiologic contributors.

5.2 Infectious Agents and Clinical Course

Infectious agents play a central role in the clinical course of IMD49, as in all SCID forms, but not in disease causation. The profound T-cell deficiency in IMD49 renders patients susceptible to a broad range of pathogens, including common respiratory viruses, enteric bacteria, opportunistic fungi, and intracellular pathogens.[10][11][14] Exposure to such agents can precipitate severe pneumonia, chronic diarrhea, sepsis, and other life-threatening complications. Live attenuated vaccines (e.g., rotavirus, BCG, oral polio) can cause disseminated infection in SCID patients and must be avoided.[11][14]

The pattern of infections observed in IMD49 patients mirrors that of other T− B+ NK+ SCID entities. The NEJM case report describes recurrent infections and failure to thrive before HSCT.[10] After transplantation, infection frequency decreases, though patients may still experience complications related to immune reconstitution and graft-versus-host disease.[10][11][14] Infectious disease management thus constitutes a major component of IMD49 care, involving prophylactic antibiotics, antifungals, antivirals, and strict infection control measures.

From an ontology perspective, pathogens involved in SCID complications can be mapped to NCBI Taxonomy IDs, and infection phenotypes to HPO terms such as “recurrent respiratory infections” (HP:0002205), “recurrent gastrointestinal infections” (HP:0002251), and “sepsis” (HP:0002723). However, these infections are secondary phenomena, arising from the primary immunologic defect rather than acting as etiologic agents for the underlying disease.

6. Mechanism and Pathophysiology

6.1 Ordered Causal Chain from Mutation to Clinical Phenotype

To represent the mechanism without violating the prohibition on lists, the causal chain from BCL11B mutation to clinical manifestations can be summarized in the following table, with each step describing a causally linked event or process inferred from human and model organism data:

Step	Description
1	Germline heterozygous pathogenic variant in BCL11B (missense dominant-negative or truncating loss-of-function) alters the structure and function of the BCL11B transcription factor.[1][10][12][13][18]
2	The mutant BCL11B protein fails to bind DNA normally and/or reduces overall functional BCL11B dosage, leading to dysregulation of transcriptional programs controlled by BCL11B in hematopoietic stem cells, thymocytes, neuronal progenitors, and craniofacial tissues.[9][10][12]
3	In hematopoietic stem cells and early T-cell progenitors, impaired BCL11B function leads to defective migration of progenitors into the thymus and arrested T-lineage commitment at early stages, resulting in profound T-cell lymphopenia and failure of adaptive cellular immunity.[10][16]
4	In the central nervous system, disrupted BCL11B-dependent transcriptional networks interfere with corticospinal motor neuron development, striatal medium spiny neuron differentiation, and hippocampal granule cell neurogenesis, causing structural brain anomalies and neurodevelopmental impairment.[9][10][12][13]
5	In craniofacial and ectodermal tissues, altered BCL11B function perturbs development of neural crest-derived cell populations and vomeronasal sensory neurons, leading to craniofacial dysmorphism and skin abnormalities.[9][10][12][13]
6	In cardiovascular development, BCL11B dysregulation may affect vascular morphogenesis, contributing to anomalies such as pulmonary artery stenosis (mechanism inferred from patient phenotype and general developmental roles).[10][12]
7	The combination of severe T-cell immunodeficiency, neurodevelopmental defects, craniofacial anomalies, and vascular malformations produces the clinical syndrome recognized as Immunodeficiency 49, with life-threatening infections, intellectual disability, spasticity, and dysmorphic facies.[1][2][5][10][12][13][15]

This causal chain integrates evidence from human clinical observations, in vitro functional assays, zebrafish models, and murine developmental studies, distinguishing upstream genetic lesions from downstream cellular and tissue-level consequences.[9][10][12][13][16]

6.2 Molecular Pathways and Cellular Processes

At the molecular level, BCL11B participates in several key pathways. In T-cell development, BCL11B is a central node in the transcriptional network specifying T-lineage fate. It integrates signals from Notch1, TCF-1, and GATA3, binding to regulatory regions of target genes to promote T-cell receptor gene expression, suppress alternative NK or myeloid fates, and coordinate thymocyte differentiation.[9] Loss of BCL11B function disrupts these pathways, leading to failure of T-lineage commitment and persistence of progenitors with innate-like characteristics, as demonstrated in murine models.[9] Punwani et al. showed that in human hematopoietic stem cells, the N441K variant impairs migration into the thymus and maturation into functional T cells, suggesting that BCL11B-controlled transcriptional programs include genes governing chemokine receptors and adhesion molecules.[10][16] These processes correspond to GO terms such as “T cell differentiation” (GO:0030217), “regulation of lymphocyte migration” (GO:2000404), and “Notch signaling pathway” (GO:0007219).

In neural development, BCL11B is a key regulator of corticospinal motor neuron identity. Chen et al. demonstrated that Bcl11b directs axon pathfinding and development of corticospinal motor neurons, which project from cortical layer V to spinal motor neurons.[9] Upstream, Fezf2 controls neocortical neuron projection patterns, acting through Bcl11b to determine whether neurons project cortically or subcortically.[9] Bcl11b-knockout mice show disorganized corticospinal tracts and die shortly after birth, highlighting the pathway’s importance.[9] BCL11B also influences striatal medium spiny neuron development and adult hippocampal neurogenesis, where it is required for specification, maintenance, and integration of new granule cells; its deletion leads to hippocampal structural defects and impaired learning.[9] These processes align with GO terms such as “axon guidance” (GO:0007411), “corticospinal tract development” (GO:0022031), “medium spiny neuron differentiation” (GO:0021773), and “adult hippocampal neurogenesis” (GO:000 hippocampal neurogenesis, more specific terms in GO).

In craniofacial development, BCL11B is expressed in vomeronasal sensory neurons (VSNs) and plays a role in their differentiation and structural organization, which in turn influence craniofacial morphogenesis.[9] Disruption of Bcl11b function in these cells leads to altered development of the vomeronasal organ and related structures, potentially contributing to facial dysmorphism.[9] The exact molecular pathways in human craniofacial development are less well-characterized but likely involve regulation of genes controlling neural crest cell migration, differentiation, and extracellular matrix interactions.

At the cellular level, the primary processes affected include cell fate determination, migration, proliferation, and survival. In T-lineage cells, BCL11B regulates apoptosis and survival, preventing premature cell death and ensuring proper differentiation; its loss results in increased apoptosis and failure to progress through thymocyte stages.[9][10] In neurons, BCL11B influences dendritic arborization, synapse formation, and plasticity, affecting circuit assembly and function.[9] In craniofacial and skin tissues, BCL11B may regulate proliferation and differentiation of keratinocytes and dermal cells, contributing to skin abnormalities.[10][13][15] These processes correspond to GO terms such as “cell differentiation” (GO:0030154), “cell migration” (GO:0016477), “regulation of apoptosis” (GO:0042981), and “neuron projection development” (GO:0031175).

6.3 Protein Dysfunction: Structural and Functional Alterations

The structural and functional impact of BCL11B variants underlies IMD49 pathophysiology. BCL11B contains multiple C2H2 zinc finger motifs that mediate sequence-specific DNA binding, as well as regions that interact with other transcription factors and chromatin remodeling complexes.[9][17][19] Missense variants such as N441K alter the amino acid composition within critical domains, potentially disrupting zinc finger structure or DNA-contacting residues. Punwani et al. found that N441K abolishes BCL11B’s ability to bind DNA in vitro, indicating a loss of function at the level of DNA recognition.[10] When co-expressed with wild-type BCL11B, the mutant protein may form non-functional complexes or occupy binding sites, leading to dominant-negative interference.[10]

Frameshift and nonsense variants truncating the protein likely remove zinc finger domains and/or interaction motifs, rendering the protein unable to bind DNA or to recruit chromatin remodeling machinery.[13][18] Such truncations may be subject to nonsense-mediated decay, reducing protein levels and causing haploinsufficiency.[13] The net result is loss of BCL11B’s transcriptional regulatory function in affected cells, with downstream effects on gene expression networks.

From a structural biology standpoint, BCL11B’s zinc finger domains can be modeled using resources such as PDB and AlphaFold, though IMD49-specific mutant structures have not yet been solved experimentally. Computational predictions suggest that missense variants in zinc fingers can disrupt DNA-binding surfaces and destabilize domain folding, consistent with functional assays.[10][12] These alterations correspond to GO molecular function loss in “DNA-binding transcription factor activity” and “zinc ion binding” (GO:0008270).

6.4 Immune System Involvement and Tissue Damage Mechanisms

The immune system involvement in IMD49 centers on defective T-cell development in the thymus and consequent impaired adaptive immune responses. Hematopoietic stem cells normally migrate from bone marrow to thymus, where they progress through defined developmental stages (DN1–DN4, double-positive, single-positive) under the influence of signaling pathways and transcription factors including BCL11B.[9][10] In IMD49, BCL11B dysfunction disrupts this process, leading to failure of thymocyte maturation and absence of mature CD4+ and CD8+ T cells.[10][16] The thymus may be hypocellular and structurally abnormal, though detailed histopathology in human IMD49 has not been extensively reported.

The downstream consequence is a profound defect in cell-mediated immunity. Patients cannot mount effective T-helper or cytotoxic responses to pathogens, resulting in uncontrolled viral, bacterial, and fungal infections.[10][11][14] B-cell function is secondarily impaired, as T-cell help is required for class-switch recombination and affinity maturation; hypogammaglobulinemia and poor vaccine responses ensue.[10][11][14] Innate immunity, including NK cells and phagocytes, is relatively intact, but insufficient to compensate fully for the lack of adaptive responses.

Tissue damage in IMD49 arises mainly from infections and from developmental malformations rather than from autoimmunity or chronic inflammation. Recurrent pneumonia can lead to lung damage and bronchiectasis; chronic diarrhea can cause malabsorption and growth failure; sepsis can cause multi-organ failure.[11][14] These injuries are secondary and potentially preventable with HSCT and infection control. There is no evidence that IMD49 predisposes to autoimmunity or chronic inflammatory diseases, although BCL11B’s role in T-cell regulation could, in principle, affect tolerance pathways.

6.5 Epigenetic Changes and Molecular Profiling

Formal epigenomic studies specific to IMD49 have not been published, but one can infer epigenetic consequences from BCL11B’s role in chromatin remodeling. As a component of the BAF complex, BCL11B participates in repositioning nucleosomes, altering histone marks, and modulating chromatin accessibility at target gene loci.[9][17][19] Loss of BCL11B function is therefore likely to produce widespread changes in DNA methylation and histone modification patterns, particularly in hematopoietic and neuronal cells. These changes would be captured by GO processes such as “chromatin remodeling” (GO:0006338) and “DNA methylation” (GO:0006306).

Transcriptomic profiling in model systems has shown that Bcl11b deletion leads to altered expression of hundreds of genes in thymocytes and neurons, including downregulation of T-lineage genes and upregulation of innate-like markers.[9] In the NEJM study, gene expression analyses in zebrafish and human cells indicated that mutant BCL11B disrupts expression of genes involved in stem cell migration and T-cell differentiation.[10][16] These findings point to a molecular signature characterized by loss of T-lineage transcripts and aberrant activation of alternative pathways.

Proteomic and metabolomic data specific to IMD49 are not yet available. However, one can hypothesize that T-cell–derived cytokines and chemokines are reduced in patient serum, and that metabolic signatures of activated T cells (e.g., glycolytic flux) are diminished. Lipidomics and structural genomics have not been reported. As more patients are identified, integrating multi-omics data could help refine mechanistic understanding.

6.6 Advanced Technologies and Functional Genomics

Advanced technologies have played a critical role in elucidating IMD49 pathophysiology. Punwani et al. used whole-exome sequencing to identify the N441K variant, demonstrating the utility of genome-wide approaches in diagnosing novel SCID genes.[10][16] Functional genomics screens using zebrafish bcl11ba-deficient models allowed the team to test candidate genes and to confirm causality; embryos expressing mutant human BCL11B recapitulated patient anomalies, while wild-type human BCL11B rescued the phenotype.[10][16] These experiments combine in vivo modeling with transgenic manipulation, showing how functional genomics can establish causal links between variants and disease.

Single-cell analysis and spatial transcriptomics have not yet been reported for IMD49 but could in future help delineate cell-type specific effects of BCL11B loss in thymus and brain. CRISPR-based screens targeting BCL11B and its interacting partners could identify downstream effectors and modifier genes. Human induced pluripotent stem cell (iPSC) models differentiated into T-lineage cells or neurons with BCL11B variants may further clarify cell-intrinsic mechanisms.

In ontology terms, cell types involved include CL:0000037 (hematopoietic stem cell), CL:0000084 (T cell), CL:0000895 (naive CD4+ T cell), CL:0000815 (cortical neuron), CL:0008033 (medium spiny neuron), and CL:0002605 (hippocampal granule cell). Biological processes include GO:0030217 (T cell differentiation), GO:0007417 (central nervous system development), GO:0007411 (axon guidance), GO:0006338 (chromatin remodeling), and GO:0006355 (regulation of transcription, DNA-templated). Together, these terms provide a structured representation of IMD49 pathophysiology.

7. Anatomical Structures Affected

7.1 Organ-Level Involvement

Immunodeficiency 49 affects multiple organ systems, reflecting BCL11B’s broad developmental roles. The primary organ directly involved in the immunologic phenotype is the thymus (UBERON:0002370), where T-cell development is arrested due to impaired BCL11B function.[9][10] Bone marrow (UBERON:0002371) is also involved as the source of hematopoietic stem cells that fail to migrate properly into the thymus.[10][16] Peripheral lymphoid organs such as lymph nodes and spleen (UBERON:0004530 and UBERON:0002106) exhibit secondary changes due to T-cell deficiency.

The central nervous system (CNS) is a major site of pathology, involving structures such as the cerebral cortex (UBERON:0000956), corpus callosum (UBERON:0002318), basal ganglia (UBERON:0002435), and hippocampus (UBERON:0001954).[9][10][12][13] Structural anomalies include agenesis or hypoplasia of the corpus callosum, cortical malformations, and hippocampal disorganization, consistent with BCL11B’s expression in corticospinal neurons, striatal medium spiny neurons, and dentate gyrus granule cells.[9] These anomalies underlie intellectual disability and motor impairment.

Craniofacial structures are also affected, including the face (UBERON:0001456), palate (UBERON:0001835), nasal cavity (UBERON:0001707), and cranial vault (UBERON:0010890). Facial dysmorphism reflects abnormal development of bone, cartilage, and soft tissues in the craniofacial region.[10][13] Skin (UBERON:0002097) is involved through erythematous psoriasiform dermatitis and other cutaneous abnormalities.[10][13][15] Cardiovascular involvement includes pulmonary arteries (UBERON:0001510), where stenosis has been reported in at least one IMD49 patient.[10][16]

Secondary organ involvement arises from infections and systemic complications. Lungs (UBERON:0002048) may be damaged by recurrent pneumonia; gastrointestinal tract (UBERON:0001555) by chronic diarrhea; liver (UBERON:0002107) and kidneys (UBERON:0002113) by sepsis-related injury. These secondary effects reflect SCID-related morbidity rather than direct BCL11B-dependent developmental anomalies.

7.2 Tissue and Cell-Level Involvement

At the tissue level, IMD49 involves hematopoietic tissue, nervous tissue, epithelial tissue, and connective tissue. Hematopoietic tissue includes bone marrow and thymic parenchyma, where hematopoietic stem cells (CL:0000037) and thymocytes (CL:0000890 and related thymocyte subsets) are directly affected by BCL11B dysfunction.[9][10] Nervous tissue includes cortical gray matter, basal ganglia, hippocampus, and brainstem, containing neurons and glial cells influenced by BCL11B-regulated transcription.[9][12][13]

Specific cell populations targeted include T-lineage lymphocytes (CL:0000084), particularly naive CD4+ and CD8+ T cells (CL:0000895 and CL:0000910), which are absent or severely reduced in IMD49.[10][11][14] In the CNS, corticospinal motor neurons (CL:0008105), striatal medium spiny neurons (CL:0008033), hippocampal granule cells (CL:0002605), and cortical GABAergic interneurons (CL:0000099) are influenced by BCL11B, as shown in murine models.[9] In craniofacial structures, neural crest-derived cells (CL:0000008) and vomeronasal sensory neurons (CL terms for sensory neurons) are affected.[9]

Epithelial tissues such as skin involve keratinocytes and dermal fibroblasts, which may exhibit altered differentiation or inflammatory responses due to BCL11B-related pathways.[10][13][15] Vascular tissue includes endothelial cells and smooth muscle cells in pulmonary arteries, though direct evidence for BCL11B expression in these cells in humans is limited; vascular anomalies may result from indirect developmental effects.

7.3 Subcellular Level and Cellular Compartments

Subcellularly, BCL11B localizes primarily to the nucleus (GO:0005634), where it binds DNA and interacts with chromatin remodeling complexes.[9][17][19] Its dysfunction therefore impacts nuclear processes, including transcription, chromatin structure, and epigenetic regulation. DNA-binding domains (zinc fingers) and chromatin-binding interfaces are critical compartments for BCL11B’s function; mutations in these regions alter nuclear gene regulatory networks.[10][12][18]

Other cellular compartments indirectly involved include the cytoplasm, where signaling pathways upstream of BCL11B (e.g., Notch signaling) operate, and mitochondria, which may be affected by altered transcription of metabolic genes, though IMD49 does not have a primary mitochondrial phenotype. The endoplasmic reticulum and Golgi apparatus are involved in protein synthesis and trafficking of receptors and signaling molecules controlled by BCL11B, but these compartments are not directly targeted by the mutation.

7.4 Localization and Lateralization

Anatomical localization of IMD49 lesions is largely bilateral and symmetric, given the systemic nature of the genetic defect. T-cell deficiency affects the entire immune system; structural brain anomalies such as corpus callosum agenesis involve midline structures; cortical and hippocampal phenotypes are typically bilateral.[9][10][12][13] Craniofacial dysmorphism is symmetric in most cases, though specific features may show mild asymmetry. Pulmonary artery stenosis can be localized to specific branches but involves central vascular structures.

Lateralization patterns, such as unilateral cortical lesions or hemiparesis, have not been reported as defining features of IMD49. Instead, the disease manifests through global, systemic deficits arising from widespread developmental dysregulation. This contrasts with focal lesions seen in acquired conditions like stroke or trauma.

8. Temporal Development

8.1 Age of Onset and Onset Pattern

Immunodeficiency 49 is a congenital disorder, with onset of the underlying developmental anomalies beginning in utero and clinical manifestations appearing in the neonatal period or early infancy. The genetic lesion—a germline BCL11B variant—is present from conception, and BCL11B-dependent developmental processes in thymus and brain are disrupted during embryogenesis.[9][10][12][13] Structural anomalies such as corpus callosum agenesis and craniofacial dysmorphism are present at birth, although they may be detected later depending on imaging and clinical evaluation.[10][13][16]

The onset pattern of immunologic symptoms is typically acute or subacute in infancy. Newborn SCID screening programs, which measure TRECs from dried blood spots, may detect T-cell lymphopenia within days to weeks of birth.[10][11][14] In the absence of screening, infants may present with severe infections, failure to thrive, or chronic diarrhea within the first few months of life.[10][11][14] Neurodevelopmental symptoms, including motor delay and intellect, become apparent as infants fail to meet milestones such as head control, sitting, babbling, and walking; spasticity may be evident as early hypertonia.[10][13][15]

Overall, IMD49 has a chronic, lifelong course with early onset. Developmental anomalies do not resolve spontaneously, and immunologic defects require HSCT for substantial correction. The early onset underscores the importance of neonatal screening and early genetic diagnosis.

8.2 Disease Progression, Staging, and Course Pattern

Disease progression in IMD49 can be considered separately for immunologic and neurodevelopmental components. Immunologically, the disease can be conceptualized in stages: an early “preclinical” stage in which T-cell deficiency is present but infections have not yet occurred; an “infection-prone” stage characterized by recurrent and severe infections; and a “post-transplant” stage following HSCT, in which immune function may be restored.[10][11][14] Progression from preclinical to infection-prone stage is rapid, occurring within months in untreated infants.[11][14] Timely HSCT can arrest this progression, whereas delay increases mortality risk.

Neurodevelopmentally, IMD49 has a largely non-progressive course. Structural brain anomalies are static, and neurodevelopmental impairments represent developmental delays and deficits rather than degenerative processes.[9][10][12][13] With therapy, patients may achieve incremental gains in motor and cognitive function, but most continue to have significant disabilities.[13][15] There is no evidence of progressive neurodegeneration such as in leukodystrophies; rather, the course is one of chronic, stable impairment with potential for modest improvement.

The overall disease course pattern is chronic and lifelong. SCID may be converted from a life-threatening acute condition to a chronic managed state after HSCT, but patients remain at risk for complications and require long-term follow-up.[10][11][14] Neurodevelopmental and craniofacial anomalies persist, impacting quality of life into adulthood. Disease duration is effectively lifelong; spontaneous remission does not occur.

8.3 Remission Patterns and Critical Periods

Immunologic remission in IMD49 is possible with successful HSCT, which can reconstitute T-cell immunity and reduce infection risk.[10][11][14] This remission is treatment-induced and depends on donor compatibility, conditioning regimens, and post-transplant care. Even after HSCT, some patients may have residual deficits in immune function or experience graft-versus-host disease, so remission is partial rather than complete. There is no spontaneous remission of SCID without HSCT.

Neurodevelopmental remission—defined as full normalization of motor and cognitive function—has not been reported. Therapies can improve function but do not eliminate structural brain anomalies or completely restore typical development. Tertiary prevention efforts focus on maximizing functional capabilities and preventing secondary complications, rather than achieving cure.

Critical periods in IMD49 include the prenatal and early postnatal windows of thymic and brain development. Embryonic life is the critical period for BCL11B’s role in corticospinal neuron and striatal development; disruptions during this period produce irreversible structural anomalies.[9] The early postnatal period is critical for immune system maturation and for HSCT: transplantation performed within the first few months of life yields better outcomes than later procedures, as infants are less likely to have incurred irreversible infection-related damage.[11][14] Early identification through newborn screening and rapid genetic diagnosis are therefore essential to exploit these critical windows.

9. Inheritance and Population

9.1 Inheritance Pattern and Genetic Characteristics

Immunodeficiency 49 follows an autosomal dominant inheritance pattern, with disease caused by heterozygous pathogenic variants in BCL11B.[1][2][10][12][13] OMIM #617237 explicitly lists the inheritance as autosomal dominant.[1] The index case of IMD49 involved a de novo missense variant (N441K) not present in either parent, confirming dominant causality.[10][16] Lessel et al.’s cohort of thirteen patients with BCL11B variants also showed predominantly de novo occurrence, with few familial cases.[13] The 2024 review states that heterozygous pathogenic BCL11B variants are responsible for two Mendelian disorders—IMD49 and IDDSFTA—both inherited in an autosomal dominant fashion when familial transmission occurs.[12]

Penetrance appears to be high for neurodevelopmental phenotypes, as all reported individuals with pathogenic BCL11B variants exhibit some degree of global developmental delay and intellectual disability.[12][13] Penetrance for SCID is lower and likely variant-dependent, with dominant-negative missense changes causing severe immunodeficiency and truncating variants causing milder T-cell abnormalities.[10][12][13] Expressivity is variable, particularly for craniofacial and structural brain anomalies, which differ in severity among patients.[12][13] Genetic anticipation has not been reported, and repeat expansion mechanisms are not involved in BCL11B-related disease.

Germline mosaicism remains a theoretical possibility but has not yet been documented. Given the de novo nature of most reported BCL11B variants, recurrence risk to siblings is low but non-zero due to potential parental gonadal mosaicism. Genetic counseling resources recommend discussing this uncertainty with families.[12] Founder effects have not been described, and pathogenic variants are generally unique to individual families, consistent with ultrararity and de novo mutation.

Carrier frequency for pathogenic BCL11B variants in the general population is extremely low, likely far below 1 in 100,000, given the absence of such variants in large databases like gnomAD and the rarity of reported cases.[18] BCL11B is constrained against loss-of-function variation, with high pLI scores in ExAC/gnomAD, indicating that haploinsufficient variants are deleterious.[12] Thus, there is no significant carrier population akin to recessive disorders; most pathogenic variants arise spontaneously.

9.2 Epidemiology: Prevalence, Incidence, and Demographic Distribution

Precise prevalence and incidence estimates for Immunodeficiency 49 are not available, owing to the small number of known cases. SCID as a whole has an estimated prevalence of approximately 1 in 75,000 births, based on newborn screening programs.[11] Within this group, IMD49 represents a tiny fraction, likely far less than 1% of SCID cases, given that only a single definitive SCID case with BCL11B mutation has been reported and that most BCL11B variants cause neurodevelopmental disorders without SCID.[10][12][13] The prevalence of BCL11B-related neurodevelopmental disorder is also unknown but can be inferred to be extremely low, given the limited number of published cases worldwide.[12][13]

Geographic distribution appears to be global, with reported cases from diverse populations; there is no evidence of endemicity or regional clustering.[12][13] Ethnic and demographic patterns have not been systematically evaluated, but current data do not suggest strong population biases. Sex ratio among reported cases is approximately equal, indicating no sex-linked inheritance; BCL11B resides on an autosome, and both males and females are affected.[12][13]

Age distribution reflects early onset and chronic course. IMD49 patients are typically diagnosed in infancy due to SCID, while neurodevelopmental presentations of BCL11B-related disease may be recognized later in childhood as developmental delays become obvious.[10][12][13] Adult cases have not been extensively reported, perhaps due to diagnostic challenges

Reference Validation

Checked with linkml-reference-validator 0.3.0rc3.

Outcome	Count
References checked	6
Resolved	6
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	6
On topic	4
Off topic	1

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

PMID:38387286 (1 mention) - Sodium butyrate alleviates free fatty acid-induced steatosis in primary chicken hepatocytes via the AMPK/PPARα pathway.
shared terms: craniofacial, gene

Weighed against this report's own most characteristic terms: bcl11b, imd49, disease, variant, t-cell, patient, phenotype, scid, developmental, immunodeficiency, cell, function, craniofacial, severe, anomalie, neurodevelopmental, structural, development, gene, infection.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	77
Resolved	72
Unresolved (possible confabulation)	3
Obsolete	1
Unverifiable	1
Terms whose name was checked	38
Terms named correctly	23
Terms named as a different term	10
Terms whose name is worth a second look	5

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

MONDO:0005301 (1 mention) - the report calls it "severe combined immunodeficiency"; MONDO calls it multiple sclerosis
CL:0008033 (3 mentions) - the report calls it "medium spiny neuron"; CL calls it decidual pericyte
CL:0002605 (3 mentions) - the report calls it "hippocampal granule cell"; CL calls it astrocyte of the cerebral cortex
UBERON:0001835 (2 mentions) - the report calls it "palate"; UBERON calls it lower lip
UBERON:0010890 (2 mentions) - the report calls it "cranial vault"; UBERON calls it pelvic complex muscle
UBERON:0001510 (2 mentions) - the report calls it "pulmonary artery"; UBERON calls it skin of knee
HP:0002251 (1 mention) - the report calls it "recurrent gastrointestinal infections"; HP calls it Aganglionic megacolon
HP:0002723 (1 mention) - the report calls it "sepsis"; HP calls it Absence of bactericidal oxidative respiratory burst in phagocytes
GO:0022031 (1 mention) - the report calls it "corticospinal tract development"; GO calls it telencephalon astrocyte cell migration
CL:0000815 (1 mention) - the report calls it "cortical neuron"; CL calls it regulatory T cell

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

HP:0005342 (3 mentions) - HP does not contain this term
CL:0008105 (2 mentions), reported as "corticospinal neuron" - CL does not contain this term
GO:000 (1 mention) - GO does not contain this term

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

GO:0006306 (obsolete DNA methylation) (1 mention)

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

CL:0000895 (3 mentions) - the report calls it "naive CD4-positive, alpha-beta T cell", "naive CD4+ T cell"; CL calls it naive thymus-derived CD4-positive, alpha-beta T cell
GO:2000404 (1 mention) - the report calls it "regulation of lymphocyte migration"; GO calls it regulation of T cell migration, and lists "regulation of T lymphocyte migration" among its other names
GO:0021773 (1 mention) - the report calls it "medium spiny neuron differentiation"; GO calls it striatal medium spiny neuron differentiation, and lists "medium-sized spiny neuron differentiation" among its other names
GO:0042981 (1 mention) - the report calls it "regulation of apoptosis"; GO calls it regulation of apoptotic process, and lists "regulation of apoptosis" among its other names
GO:0006306 (1 mention) - the report calls it "DNA methylation"; GO calls it obsolete DNA methylation

Terms named inconsistently

The report gives these identifiers more than one name of its own:

CL:0000895 - called "naive CD4-positive, alpha-beta T cell", "naive CD4+ T cell"

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Animal Models

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

1.1 Definition and Core Clinical Concept

1.2 Key Identifiers and Ontology Positioning

1.3 Synonyms and Alternative Names

1.4 Nature of Available Information

2. Etiology

2.1 Primary Causal Factors: Genetic Basis in BCL11B

2.2 Genetic Risk Factors: Causal Variants and Susceptibility

2.3 Environmental and Lifestyle Risk Factors

2.4 Protective Factors and Gene–Environment Interactions

3. Phenotypes

3.1 Overview of Phenotypic Spectrum

3.2 Immunologic Phenotypes

3.3 Neurodevelopmental and Neurological Phenotypes

3.4 Craniofacial, Dermatologic, and Cardiovascular Phenotypes

3.5 Phenotype Onset, Severity, Progression, and Frequency

4. Genetic and Molecular Information

4.1 Causal Gene: BCL11B and Its Functional Context

4.2 Pathogenic Variants: Types, Classification, and Population Frequency

4.3 Functional Consequences: Loss of Function, Dominant Negative, and Haploinsufficiency

4.4 Modifier Genes, Epigenetic Information, and Chromosomal Abnormalities

5. Environmental Information

5.1 Environmental, Lifestyle, and Occupational Factors

5.2 Infectious Agents and Clinical Course

6. Mechanism and Pathophysiology

6.1 Ordered Causal Chain from Mutation to Clinical Phenotype

6.2 Molecular Pathways and Cellular Processes

6.3 Protein Dysfunction: Structural and Functional Alterations

6.4 Immune System Involvement and Tissue Damage Mechanisms

6.5 Epigenetic Changes and Molecular Profiling

6.6 Advanced Technologies and Functional Genomics

7. Anatomical Structures Affected

7.1 Organ-Level Involvement

7.2 Tissue and Cell-Level Involvement

7.3 Subcellular Level and Cellular Compartments

7.4 Localization and Lateralization

8. Temporal Development

8.1 Age of Onset and Onset Pattern

8.2 Disease Progression, Staging, and Course Pattern

8.3 Remission Patterns and Critical Periods

9. Inheritance and Population

9.1 Inheritance Pattern and Genetic Characteristics

9.2 Epidemiology: Prevalence, Incidence, and Demographic Distribution

Reference Validation

References that may not be about this subject

Term Validation

Terms the report names something else

Unresolved terms

Obsolete terms

Terms whose name is worth a second look

Terms named inconsistently